NUCLEIC ACID MOLECULE ENCODING A 11-CIS RETINOL DEHYDROGENASE

Abstract: In accordance with this invention, an RPE cell membrane associated protein which has a molecular weight of about 32 kDa, as determined by SDS-PAGE, has been discovered. This protein, referred to an "p32" forms an oligomeric protein complex with the previously characterized p63 protein, a component of the membrane receptor for RBP. A nucleic acid molecule which codes for the p32 protein has also been isolated and sequence analysis shows that the p32 protein belongs to the family of short chain alcohol dehydrogenase, and exhibits 11-cis-retinol dehydrogenase activity, the enzyme which catalyzes conversion of 11-cis-retinol into 11-cis-retinaldehyde.

Description: "NUCLEIC ACID MOLECULE ENCODING A 11-CIS RETINOL DEHYDROGENASE' Related Applications This application is a continuation-in-part of Serial No. 08/562,114, filed November 22, 1995, which is a continuation-in-part of Serial No. 08/375.962, filed on January 20, 1995, which is a continuation-in-part of copending application Serial No. 08/258,418, filed on June 10, 1994. All of these applications are incorporated by reference. Field of the Invention This invention relates to a protein having ll-cis retinol dehydrogenase activity, and which forms a complex with a specific portion of a membrane receptor for plasma retinol-binding protein (RBP) expressed, e.g., in retinal pigment epithelium (RPE) , and more specifically a 32 kDa protein having ll-cis retinol dehydrogenase activity, which forms a complex with a 63 kDa RBP-binding membrane protein. The invention also involves isolation of the 32 kDa protein (p32) , as well as nucleic acid molecules coding for p32 or complementary to coding sequences therefor, in addition to various applications of these materials. Background of the Invention Retinoids (vitamin A-derivatives) have important physiological functions in a variety of biological processes. During embryonic growth and development, as well as during growth and differentiation of adult organisms, retinoids act as hormones and participate in the regulation of gene expression in a number of cell types. See Lied et al . Trends Genet., 17:427-433 (1992) . It is believed that these effects are mediated through two classes of nuclear ligand-controlled transcription factors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs) , Benbrook et al . , Nature, 333:669-672 (1988) ; Brand et al . , Nature, 332:850-853 (1988) ; Giguere et al., Nature, 330:624-629 (1987) ; Mangelsdorf et al . , Nature, 345:224-229 (1990) ; Mangelsdorf, et al . Genes Dev. 6: 329-344 (1992) ; Petkovich et al . Nature 330:440-450 (1987) ; and Zelent et al . , Nature 339:714-717 (1989) . Apart from their role as hormones in cellular growth and differentiation, retinoids are also involved in the visual process as the stereo isomer ll-cis retinaldehyde of retinaldehyde is the chromophore of the visual pigments. See, e.g. Bridges, The Retinoids. Vol. 2, pp 125-176, Academic Press, Orlando, Florida, (1984) . Under normal physiological conditions most cells, both ocular and non-ocular, obtain all-trans retinol as their major source of retinoids. Despite the many different metabolic events taking place in different tissues, it is known that a common extracellular transport machinery for retinol has evolved. Specifically, in plasma, retinol is transported by plasma retinol binding protein (RBP) . See Goodman et al . , The Retinoids, Academic Press, Orlando Florida, Volume 2, pp. 41-88 (1984) . The active derivatives of retinol, i.e., retinoic acid in non-ocular tissues and mostly ll-cis retinaldehyde for ocular tissues, are then generated by cellular conversion using specific mechanisms. To date, none of these mechanisms have been fully defined at the molecular level and several of the enzymes involved have only been identified by enzymatic activities. See Lion et al. , Biochem. Biophys. Acta. 384:283-292 (1975) ; Zimmermann et al. , Exp. Eye Res. 21:325-332 (1975) ; Zimmermann, Exp. Eye Res. 23:159-164 (1976) and Posch et al . , Biochemistry 30:6224-6230 (1991) . Polarized retinal pigment epithelial cells (RPE) are unique with regard to retinoid uptake since all-trans retinol enters these cells via two different mechanisms. Retinol accumulated from RBP is taken up through the basolateral plasma membrane, while all-trans retinol, presumably taken up from the interstitial retinol-binding protein (IRBP) following bleaching of the visual pigments, may enter through the apical plasma membrane. See Bok et al., Exp. Eye Res. 22:395-402 (1976) ; Alder et al. , Biochem. Biophys. Res. Commun. 108:1601-1608 (1982) ; Lai et al., Nature 298:848-849 (1982) ; and Inu et al. , Vision Res. 22:1457-1468 (1982) . The transfer of retinol from RBP to cells is not fully understood. In a number of cell types., including RPE. specific membrane receptors for RBP have been identified, which is consistent with a receptor-mediated uptake mechanism for retinol. For example, isolated retinol binding protein receptors, nucleic acid molecule coding for these receptors and antibodies binding to the receptor have been taught, in references relating to the first of the two mechanisms. See Bavik et al . , J. Biol. Chem. 266:14978- 14985 (1991) ; Bavik, et al . J. Biol. Chem. 267:23035-23042 1992; Bavik et al . , J. Biol. Chem. 267:20540-20546 (1993) ; and copending U.S. Application Serial No. 083,539 and International Publication WO 93/23538, all of which are incorporated by reference herein. See also Heller, J. Biol. Chem. 250:3613-3619 (1975); and Bok et al . , Exp. Eye Res. 22:395-402 (1976) . Retinol uptake on the apical side of the RPE for the regeneration of ll-cis retinaldehyde is less well characterized. Regardless of the origin of all-trans retinol, however, the synthesis and apical secretion of ll- cis retinaldehyde seems to be the major pathway for accumulated retinol in the RPE. At present, it is not known whether similar mechanisms are used with regard to cellular retinol uptake through the basolateral and the apical plasma membranes. Available data do show that functional receptors for RBP are exclusively expressed on the basolateral plasma membrane of RPE-cells. Bok et al . , Exp. Eye Res. 22:395-402 (1976) . It is also known that pigment RPEs express a 63 kDa protein (p63) . This molecular weight, and all others, is by the refernce to SDS-PAGE, unless stated otherwise. It has also been shown by chemical cross-linking that this protein may be part of an oligomeric protein complex which functions as a membrane receptor for plasma retinol-binding protein (RBP) in RPEs, or a component of the retinoid uptake machinery in RPE cells. See Bavik et al, J. Biol. Chem. 266:14978-14875 (1991) ; Bavik et al.. J. Biol, Chem. 267:23035-23042 (1992) , and U.S. Application Serial No. 083,539 and PCT application W093/23538. The p63 protein has been isolated and the corresponding cDNA cloned. See Bavik et al . , J. Biol. Chem. 267:20540-20546 (1993) . However, there is nothing in these references suggesting the existence of the protein which is a feature of this invention. Summary of the Invention In accordance with this invention, RPE membrane associated proteins which have a molecular weight of about 32kd, as determined by SDS-PAGE, has now been discovered. These proteins, referred to as "p32," form oligomeric protein complexes with the previously characterized p63 protein, a component of the membrane receptor for RBP. Also disclosed are nucleic acid molecules which code for the p32 protein. Sequence analysis shows that the p32 protein belongs to the family of short chain alcohol dehydrogenases, and exhibits ll-cis retinol dehydrogenase activity, the enzyme which catalyzes the stereospecific conversion of 11-cis-retinol into ll-cis retinaldehyde in the presence of cofactor NAD+. As will be shown, p32 has many important uses. For example, owing to its membrane bound 11-cis-retinol dehydrogenase activity, which catalyzes the conversion of 11-cis-retinol to 11-cis-retinaldehyde, a major metabolic step in retinoid metabolism in RPE-cells, retinoid accumulation and metabolism which may lead to retinitis pigmentosa, may be directly or indirectly tied to the presence of p32, and/or its activation or inhibition. As p32 has also been found to be a member of the short chain alcohol dehydrogenase super family, many known alcohol dehydrogenase inhibitors (and activators) are available to develop activity assays, and thus diagnostic materials for retinol uptake, and ocular retinoid metabolism. Also a part of this invention are nucleic acid molecules which encode mammalian forms of the proteins, such as the human, bovine, and murine forms. Also a part of the invention are probes, based upon the nucleotide sequences described herein. These and other aspects of this invention are more fully discussed in the following Detailed Discussion with accompanying drawings . Brief Description of the Drawings FIG. IA shows SDS-PAGE analysis of radiolabeled protein from RPE-membranes and immunoprecipatation with mAb A52 against p63. FIG. IB shows SDS-PAGE analysis of RPE-membrane proteins bound and eluted through an mAb A52 immunoaffinity column, and the presence of p32 in the eluted faction from the immunoaffinity column. FIG. 2A shows visualization in agarose gel electrophoresis of a 61 bp PCR-amplified fragment using oligonucleotide mixtures OM1 and OM3, both derived from peptide 321 deduced from partial amino acid sequence determination of trypsin digested p32. FIG. 2B shows visualization of a 330 bp PCR-amplified fragment using oligonucleotide mixtures OM2 and OM3 , derived from peptides p323 and p321, respectively, as deduced from partial amino acid sequence determination of trypsin digested p32. FIG. 3 illustrates the nucleotide sequence of pλ321 and the deduced amino acid sequence of p32, with the partial amino acid sequences determined from peptides isolated from trypsin digested p32. FIG. 4 illustrates amino acid sequence alignments of p32 and some related proteins belonging to the family of short-chain alcohol dehydrogenases. FIG. 5 illustrates analysis of the amino acid sequence of p32. FIG. 6 illustrates membrane interaction of p32 synthesized in vitro. FIG. 7 illustrates the restricted expression of transcripts corresponding to p32. FIG. 8A illustrates expression of p32 in transfected cells for further enzymatic activity analysis of ll-cis retinol dehydrogenase activity. FIG. 8B illustrates the expression of ll-cis retinol dehydrogenase activity in the presence of NAD+ as indicated by the formation of ll-cis retinaldehyde. FIG. 8C illustrates the lack of 11-cis-retinol dehydrogenase activity in the presence of cofactor NADP. FIG. 8D illustrates control cells not expressing p32 which lack the ability to oxidize 11-cis-retinol into 11- cis-retinaldehyde . Figure 9 shows the structure of the human 11-cis- retinol dehydrogenase gene. Detailed Discussion of Preferred Embodiments It is known that plasma retinol binding protein (RBP) can be chemically cross-linked to a high molecular weight complex of a 63 kDa protein (p63) receptor of retinal pigment epithelium membranes (RPE) , forming an RBP-RBP receptor complex with elution properties of globular proteins of similar sizes having apparent molecular weights of approximately M r 150,000 and 450,000. See Bavik et al, J. Biol. Chem. 266:14978-14875 (1991) , and Bavik et al . , J. Biol. Chem. 267:23035-23042 (1992) . The protein responsible for binding of RBP, expression of which is restricted to RPE, has been identified as a 63 kDa protein (p63) . Through the generation of a monoclonal antibody A52 (mAb A52) to the 63 kDa protein which binds the RBP-RBP receptor complex and p63, and immunoaffinity chromatographic analysis, a majority of p63 is eluted as a monomer, with a significant portion of the protein found in positions corresponding to higher molecular weight species. This indicates that p63 exists in an oligomeric protein complex with other protein components. Bavik et al . , J. Biol. Chem. 266:14978-14985 (1991) , and Bavik et al, J. Biol. Chem. 267:23035-23042 (1992) . Therefore, the following procedure was carried out to investigate the molecular characteristics of such oligomeric protein complexes, and whether p63 forms a complex with other proteins specific to RPE. The results show that a 32 kDa membrane associated protein (p32) indeed forms a complex with p63. Example 1 Bovine RPE-cells were isolated and membrane fractions were prepared as described in Bavik et al, J. Biol. Chem. 266:14978-14875 (1991) incorporated by reference. RPE- membrane proteins were then solubilized in phosphate- buffered saline (PBS) (20 mM sodium phosphate, ph 7.2, containing 150 mM NaCl) , containing 1% 3- [ (3-cholamido- propyl) -dimethylammonio] -1-propane sulfonic acid (CHAPS) at 1 mg of total membrane protein/ml of buffer. Remaining material was removed by ultracentrifugation at 100,000 x g for 1 hour. Next, 500 ul aliquots of the solubilized membranes were subjected to gel filtration on a Sepharose 6 column equilibrated in PBS containing 1% CHAPS. The column was operated at a flow rate of 0.2 ml/min and 500 ul fractions collected. Proteins eluted in fractions corresponding to globular proteins of M r 150,000 to 400,000 were then radiolabelled with Na 15 I using the well-known Chloramin T procedure. Non-incorporated 125 I was removed by gel filtration on Sepahadex G-25 packed in a Pasteur pipette. Aliquots of the radiolabelled proteins were then diluted in PBS containing 1% CHAPS and 1% bovine serum albumin and subsequently subjected to immunoprecipitation using the mAb A52 to p63 (5 ug per incubation) or using two polyclonal rabbit antisera to p63 (3 ul of serum per incubation) See Bavik et al., J. Biol. Chem. 267:23035- 23042 (1992) . Non-specific immunoprecipitation was monitored in parallel incubations using an unrelated mAb and preimmune rabbit serum. Fifty ul of a 50% slurry of protein A-Sepharose was added to the incubations for 30 minutes. The beads were subsequently carefully washed with PBS containing 1% CHAPS and the eluted material then prepared for SDS-PAGE analysis, was carried out according to Blobel et al . J. Cell. Bio. 67:835-851 (1975) . Referring now to FIG IA, autoradiograms of the SDS- PAGE gels showed that both types of reagents reacted with p63, whereas the unrelated mAb or preimmune rabbit serum did not precipitate p63. In all lanes containing immunoprecipitated p63 there was an enrichment of a M r 32,000 protein. Since both mAb A52 and the rabbit antisera to p63 are highly specific for p63 (See, for example, Bavik et al., J. Biol. Chem. 267:23035-23042 (1992)) , it can be concluded that the M r 32,000 protein (p32) coprecipitated in the aforesaid analysis by binding to p63. The analysis also identified a double band of M r 50, 000-52, 000 which precipitated along with p32 and p63 (FIG. I d, e) . Example 2 Experiments were then carried out to identify p32. Advantage was taken of the fact that p32 specifically interacts with p63 as shown supra. Thus, detergent solubilized RPE-membrane proteins were passed over an immunoaffinity column containing mAb A52. Referring now to FIG. IB, lane b, following a washing procedure, bound proteins were eluted at high pH in a CHAPS-containing buffer, and SDS-PAGE analysis and Coomassie staining of the eluted fractions revealed p63 to be specifically retained and eluted from the immunoaffinity column. Further, a weekly stained band corresponding to p32 could be visualized in the eluate from the A52 column. As shown in FIG. IB, a comparison of the total protein profile of solubilized RPE membranes and the eluted fraction from the A52 column show that the p32 protein is not efficiently retained therein. However, the appearance of p32 in the eluted fraction from the A52 column, but not in the eluted fraction from the column containing an unrelated lg, indicate a specific interaction of p32 with p63. This result is consistent with previous immunoprecipitation data, and shows that p32 is complexed to p63 and is retained on the immunoaffinity column due to this complex formation. Following identification of p32 as a component of a complex with p63 in RPE- embranes, the p32 protein itself was isolated by SDS-PAGE of eluted fractions of solubilized RPE-membranes from the A52 immunoaffinity column, as set forth below in Example 3. Example 3 RPE-membranes were solubilized in PBS containing 1% CHAPS as set out above and then incubated with mAb A52 lg coupled to CNBr-activated Sepharose 4B beads (Pharmacia) in a Bio-Rad poly prep column (Bio-Rad) by end-over-end rotation at +4°C. Following a 2 hour incubation, the beads were allowed to settle and the column was quickly washed with 5 column volumes of PBS containing 1% CHAPS. Bound proteins were then eluted with 50 mM triethanolamine buffer (pH 11.2) containing 1% CHAPS. The pH of the eluate was quickly adjusted to 8.0 by the addition of 1 M Tris-HCl buffer containing 1% CHAPS. The eluted fractions were subjected to SDS-PAGE, and the separated proteins then visualized by Coomassie Blue staining. A band corresponding to p32 (SDS-PAGE, 32kDa) , was found. To determine the primary structure of p32 partial amino acid sequence analysis of the isolated protein was undertaken by first cutting out a portion of the aforesaid Coomassie stained band corresponding to approximately 2-5 ug of the 32kDa protein, then lyophilizing the gel piece to dryness. The gel was rehydrated in buffer containing modified trypsin and incubated to generate various peptides for extraction and analysis. A preferred procedure is set forth below in Example 4. Example 4 Coomassie stained bands containing the p32 protein from Example 2 were excised and treated according to Rosenfeld et al . Anal. Biochem. 15:173-179 (1992) with minor modifications. The gel pieces were washed twice for 30 min at 30°C with 100 ul of 0.2 M ammonium bicarbonate buffer containing 50% acetonitrile and thereafter completely dried under a stream of nitrogen. The gel pieces were subsequently rehydrated with 5 ul of 0.2 M ammonium bicarbonate buffer containing 0.02% Tween 20 and 0.5 ug of modified trypsin. Trypsin was added from a stock solution prepared in 1 mM HCl. Rehydration was continued by the addition of 5 ul portions of the 0.2 M ammonium bicarbonate buffer until the gel pieces rehydrated to their original sizes. The rehydrated gel pieces were then incubated overnight at 30°C. Protease activity was inhibited by the addition of trifluoroacetic acid (TFA) to a final concentration of 1%. The supernatant was recovered and combined with two extracts made with 150 ul of 0.1% TFA in 60% acetonitrile. The organic phase was reduced and the digest was subjected to HPLC using a reverse phase mRPC C2/C18 SC 2.1/10 column operated in a SMART system. The sample was eluted with a gradient of acetonitrile in 0.065% TFA and fractions containing discrete peptides were collected using the automatic peak fractionation option. Five of the identified peptides were selected for amino acid sequence analysis using an ABI 470A sequencer equipped with a model 120A PTH analyzer (applied Biosystems Inc. Foster City, CA) . The results are set forth below in Table 1. TABLE 1 Amino acid sequences determinations of five peptides isolated from trypsin digested p32. p321 L-V-E-A-V-L-A-E-V-L-P-K-P-A-Q-T-V-A (SEQ ID NO: 1) (D) a (W) (Y) P322 Y-S-P-G-W-D-A-K (SEQ TD NO: ?. ) P323 T-P-V-T-N-L-E-T-L-E-D-T-L-Q-A (SEQ ID NO: 3) P324 D-V-A-P-F-G-V (SEQ ID NO: 4) P325 L-H-T-T-L-L-D-V-T-D-P-Q-S-I (SEQ ID NO: 5) a The amino acid residues given within the parentheses are the residues deduced from the cDNA sequence in the same positions . Protein SEQ ID NOS: 1-5 can be used alone or ligated to hapten by well known methods. Next, to determine the complete primary structure of p32, four degenerative oligonucleotide mixtures, OM1-OM4, as set forth below in Table 2 were synthesized based on the amino acid sequences of the p321 and p323 sequenced peptides of Table 1. The procedure is as follows in Example 5. Example 5 Four degenerate oligonucleotide mixtures derived from peptides p321 and p323 were synthesized using well-known techniques. The two sense mixtures (0M1 and 0M3) were derived from the N-terminal amino acids 1-5 of p321 and 2-6 of p323. The antisense mixtures (OM2 and OM4) were derived from amino acids 12-17 of p321 and 10-15 of p323. All nucleotide mixtures were synthesized with a 4 bp 5' extension and an Eco Rl-site for subsequent cloning of the PCR products. The sequences of the oligonucleotide mixtures are set out below in Table 2, and the Eco Rl-site is underlined. Positions containing all four bases are marked N. TABLE 2 0M1:ACGT GAA TTC TN GTN GA(A,G)GCN GT (SEQ ID NO: 6) 0M2:ACGT GAA TTC AC NGT(T,C)TG NGC NGG(T,C)TT (SEQ ID NO: 7) OM3:ACGT GAA TTC CCN GTN ACN AA(T,C) (C,T)T (SEQ ID NO: 8) OM4 :ACGT GAA TTC GC(T,C)TG NA(A,G) GT (A,G) TC(T, C) TC (SEQ ID NO: 9) Single stranded "complementary" cDNA from reverse transcribed RPE mRNA and four combinations of the above- described degenerate nucleotide mixtures were employed in polymerase chain reactions (PCR) using a standard procedure. Following the amplification procedure, aliquots of the PCR reaction products were analyzed by agarose gel electrophoresis . The procedure is set out below in Example 6. Example 6 To carry out the PCR amplifications, first strand cDNA was synthesized by standard procedures using avian myelostosis virus reverse transcriptase. Twenty ug of total RNA from isolated RPE-cells were used and the reaction was primed with oligo (dT) 15. Aliquots corresponding to 2 ug of total RNA was used in each subsequent PCR reaction. The PCR reactions were performed using a final concentration of 0.5 uM of the oligonucleotide mixtures in a 100 ul reaction. Taq polymerase was used. Following 30 cycles (2 minute at 95°C, 1 minute at 55°C and 2 minute at 72°C) , aliquots of the reactions were analyzed on 4% GTG agarose gel containing 5 ug/ml of ethidium bromide. As shown in FIG. 2A, amplifications using the oligonucleotide mixtures OMl and 0M2, both derived from peptide p321, resulted in an amplified 61 bp fragment. Amplifications using mixtures OM3-OM4 and 0M1-0M4 failed to yield any products. Finally, as shown in FIG. 2B, amplification using OM3-0M2 resulted in an amplified 330 bp fragment . Subsequent sequence analysis of the 61 bp and 330 bp fragments confirmed that cDNA sequences have been amplified which corresponded to the peptide sequences generated in the previous amino acid sequence analysis. Differences between the deduced amino acid sequences from amplified PCR fragments and the generated amino acid sequence of peptide p32l indicates the generation of specific probes suitable for the isolation of full length cDNA clones encoding p32. To isolate a full length cDNA clone, an RPE-specific lambda ZAP-II cDNA library was screened with the 330 bp fragment as the probe . Five independent lambda clones were isolated from approximately 200,000 clones, and subcloned by in vivo excision. The cDNA clone pλ321 contained the longest insert, (approximately 1.1 Kb) , and was selected for use in further studies. Both strands of pλ321 were fully sequenced with the insert being 1104 bp long, excluding linkers used to prepare the cDNA library. The procedure is set out below in Example 7. Example 7 The amplified products using OM1-OM2 (61 bp) and OM3- OM2 (330 bp) were digested with EcoRl, gel purified and cloned into EcoRl-cut vector pBS. The 32 P-labelled 330 bp fragment was used to screen a RPE-specific λZAP II cDNA library as previously described by Bavik et al., J. Biol. Chem. 267:20540-20546 (1993), incorporated by reference. Five positive λ clones were isolated and the inserts were subcloned in pBluescript by in vivo excision following the manufacturer's instructions. Clone pλ321 contained an insert of 1.1 Kb, and both strands were fully sequenced using Sequenase with T3, T7 or M13 universal primers or with internal primers . The nucleotide sequence of pλ321 and the predicted amino acid sequence of p32 are shown in FIG. 3 (SEQ ID NO: 10) . Nucleotides are numbered on the left and amino acid residues on the right. Amino acid 1 is initial methionine ("Met") . As shown in FIG. 3, the 1.1 kbp insert contains one long open reading frame encoding 318 amino acid residues with a calculated mass of 35,041D. The first methionine residue lies in a good context according to the Kozak rules for transcription initiation and is likely to be the initiation codon. See Kozak, Cell, 44:283-292 (1986) . This inference is strengthened by the fact that in vitro translation of synthetic mRNA transcribed from pλ321 gives rise to a M r 32,000 protein (SDS-PAGE analysis) , as set out below, but there is no stop codon in frame in the upstream 35 bp 5' -untranslated region of the cDNA. As also shown in FIG. 3, the 100 bp 3 ' -untranslated region ends with a putative polyA-tract, and a polyA-signal was identified in the upstream sequence (bp 1104-1110) . The deduced amino acid of pλ321 and the amino acid sequences of the five generated tryptic peptides (Table 1) differ in only 3 positions out of the 62 residues available for a comparison. All 3 differences are found in the peptide p321 but the nucleotide sequence in this region of a second cDNA clone (pλ324) is identical to that of pλ321. This indicates that the amino acid sequence determination of peptide p321 was probably incorrect although it cannot be excluded that the differences are due to the presence of different alleles of p32. These data demonstrate that pλ321 contains the complete coding region of p32. Again, referring to FIG. 3, a consensus sites for N- linked glycosylation (amino acid residues N-I-T) could be found in the deduced amino acid sequence at position 160- 162. Additionally, it has been found that p32 shows sequence similarities to short-chain alcohol dehydrogenases . Referring now to FIG. 4 a search through the Swissprot protein data base revealed that p32 is structurally related to several previously sequenced proteins. It is most closely related to a mitochondrial matrix dehydrogenase, the D-j3-hydroxybutyrate dehydrogenase (BDH) Churchill et al; Biochem. 31:3793-3799 (1992) and shows less but significant similarities to two other proteins, the 3-oxoacy[acyl carrier protein] reductase from E. coli (Rawlings et al., J. Biol. Chem. 267-5751-5754 (1992)) and the human estradiol 17 β-dehydrogenase (Peltoketo et al . , FEBS Lett., 239:73-77 (1988) and Leu et al., Mol. Endocrinol. 3:1301-1309 (1989)) . All the related proteins fall into the protein super-family of short- alcohol dehydrogenases. This protein superfamily comprises approximately 50 different proteins (Persson et al, Eur. J. Biochem, 200:537-593 (1991)) . The overall sequence homology between p32 and BDH is around 39%. The level of homology to the E. coli reductase and to the estradiol 17- β-dehydrogenase is lower (31% and 33%, respectively) . Optimal multiple alignment identified several conserved regions shared by p32 and the most closely related proteins (boxed areas in FIG. 4) . The first region involving residues 63-69 (using the numbering in FIG. 4) which displayed the conserved motif G-X-X-X-G-X-G is believed to be the binding site for cofactors NAD, NADP or its reduced forms. Another conserved region is found between residues 148-153 (consensus sequence L-V-N-N-A-G) but no functional characteristics have yet been attributed to that sequence motif. The sequence motif Y-X-X-X-K, thought to be the active site, is the most highly conserved motif in short-chain alcohol dehydrogenases and is present in p32 residues 175-179 See Persson et al. , Eur. J. Biochem, 200:537-593 (1991) . These similarities demonstrate that p32 exhibits several features of a functional short-chain alcohol dehydrogenase. As shown in FIG. 5, hydropathy analysis of the amino acid sequence of p32 reveals several hydrophobic stretches, indicating that p32 is a membrane-associated protein. The first 18 amino acids are hydrophobic, and this region has characteristics of a classical signal sequence. However, a consensus site for signal peptidase cleavage could not be identified. See Von Heijne, Nucl . Acid Res., 14:4683-4690 (1986) . The amino acids between residues 130 to 150 are hydrophobic and there is a relatively long hydrophobic stretch near the C-terminus of the protein. Thus, p32 displays several hydrophobic regions which are potential membrane spanning segments . In light of the homology to the family of short-chain alcohol dehydrogenases as shown above, it is likely that the central hydrophobic region of p32 (residues 130-150) is not used as a membrane anchor. Instead, both the N-terminal and the C-terminal regions are potential membrane anchoring domains. To determine the mode of interaction of p32 with membranes, p32 was synthesized by in vitro translation using a reticulocyte lysate system with mRNA transcribed from linearized pλ321. The procedure is set out in Example 8 below: Example 8 Expression of p32 by in vitro translation In vitro transcribed mRNA encoding p32 was synthesized from linearized Pλ321 using T7 RNA polymerase. In vitro translation reactions were carried out using nuclease treated rabbit reticulocyte lysate following the manufacturer's instructions. Fifty ng of mRNA was included in each reaction, with or without the addition of dog pancreatic microsomes. To isolate membrane inserted p32, the microsomes were collected by centrifugation at 12,000 x g for 10 min at 4°C. The microsomes were carefully resuspended in PBS and recentrifugated. As shown in FIG. 6, translation in the presence of dog pancreatic microsomes showed that p32 becomes almost quantitatively membrane associated and migrates as a M r 32,000 species in SDS-PAGE. Translation in the absence of acceptor membranes similarly yields a M r 32,000 protein. These data indicate that the N-terminal hydrophobic sequence acts as a signal sequence but it is not removed by the signal peptidase, and such supports the previous observation that a consensus site for signal peptidase cleavage could not be identified in the deduced primary s uen e , The tissue expression of p32 was analyzed by Northern blotting analyses using total RNA isolated from bovine RPE, liver, kidney, adrenal, lung, testis, brain and muscle. The procedure is set out in Example 9. Example 9 Northern blot analyses Twenty ug of total RNA isolated from a number of tissues was electrophoresed on a 1% agarose under denaturing conditions and transferred to a Hybond-N nylon filter. The filter was hybridized with 32P-labelled full length cDNA encoding p32 under stringent conditions. The details of the isolation of total RNA, hybridization conditions and washing procedure were identical to those previously described in Bavik, et al . , J. Biol. Chem. 267:20540-20546 (1993) . Hybridization at high stringency with the 1.1 Kb insert of pλ321 as the probe, revealed abundant expression of transcripts corresponding to p32 only in RPE but not at a detectable level in several other tissues. The size of the major transcript was 1.4 kb but other less abundant transcripts could be visualized after prolonged exposure of the filters both in RPE as well as in other tissues. Example 10 Expression of p32 in COS-cells and enzymatic analysis of the properties of recombinant p32. p32 was first expressed in COS-cells using a eukaryotic expression vector, and then microsome fractions from transfected cells and control cells were subjected to immunoblotting analysis to verify the expression of p32 at the desired levels, as follows: Specifically, the EcoRI - insert of p λ 321 was cloned into the EcoRI-digested eucaryotic expression vector pSG5. See Green et al . , Nucl . Acid Res. 16:39 (1988) . COS-cells were maintained in Dulbecco's minimal essential medium supplemented with 10% fetal bovine serum, 2mM glutamine and antibiotics. The cells were seeded into 60 mm petri dishes (4 x 10 5 cells per dish) and transfected with 5 ug of plasmid per dish using DEAE dextran. Control cells were transfected with equal amounts of the parental vector alone. After treatment with 10% DMSO for 2 minutes, the cells were incubated for 72-96 hours, and then harvested by scraping the dishes with a rubber policeman, and the cells thereafter collected by low speed centrifugation. The collected cell pellets were next resuspended in hypotonic buffer (10 mM Tris-HCl, pH 7.5 containing ImM phenyl- methylsufonyl fluoride) , put on ice for 20 minutes, and then homogenized using a Dounce homogenator. Unbroken cells and debris were removed by centrifugation (3000 x g) for 15 minutes. Microsomes were subsequently collected by ultra-centrifugation at 100,000 xg for 1 hour; membrane pellets were stored at -80°C until further analyzed. Antisera to p32 were generated by injecting rabbits with p32 (amino acid residues 19-318) expressed as a fusion protein with GST. The bacterial expression vector pGEX 2T was used and induction and GST-fusion protein was induced and purified, as recommended by the supplier (Pharmacia) . Each rabbit received a subcutaneous injection of 75 ug of fusion protein emulsified in Freunds complete adjuvant. The rabbits were boostered with 50 ug of fusion protein emulsified in Freunds incomplete adjuvant every second week. Blood was collected every second week. The immune rabbit sera were passed over a column containing GST fusion-protein immobilized on CNBr activated Sepharose beads. Bound lg was eluted with 0.1 M sodium citrate buffer (pH 3.0) , containing 0.5 M NaCl. To remove lg to the GST portion of the fusion protein, the eluted lg was similarly incubated with GST-coupled Sepharose beads and the unbound lg fraction was used. For immunoblot analysis of the over expressed protein, the lg was used at a concentration of 1 ug per ml. The details of the immunoblotting procedure are described in detail in Bavik et al., J. Biol. Chem., 267:23035-23042 (1992) the disclosure of which is herein incorporated by reference. As shown in FIG. 8A, the above procedure resulted in expression of p32 in cells transfected with the recombinant expression vector, but not in control cells that were mock transfected. Next, the enzymatic properties of p32 expressed in COS-cells was assayed in a manner similar to that as described in the study of 11-cis-retinol dehydrogenase activity in microsomal fractions of RPE cells. See Saari et al., Anal. Biochem 213:28-13226 (1993) . In particular, the enzymatic activity of p32 was confirmed by incubating the microsomal fractions from the aforementioned transfected cells, and from control cells lacking p32, with varying combinations of the different stereo isomeric substrates, i.e., 11-cis-retinol or all- trans-retinol, in the presence of either cofactor NAD+ or NADP. To prepare the substrate, ll-cis retinol was synthesized from 11-cis-retinaldehyde using sodium borohydride, as set fourth in Heller et al. , J. Biol. Chem. 248:6308-6316 (1973) , and stored under argon at 80°C. HPLC analysis confirmed the quantitative reduction of 11-cis- retinaldehyde to 11-cis-retinol, and all manipulations with the retinoids were done under subdued lighting conditions. To assay for p32 activity in transfected cells, the final concentration of 11-cis-retinol and all-trans-retinol (obtained from Sigma Chemical Co.) in the incubations was reduced to 100 uM. Twenty ug of total membrane protein from COS-cells expressing p32 or from control cells were used in each incubation, and thereafter a 30 minute incubation at 37°C in the presence or absence of NAD+ or NADP followed. Reaction mixtures were then extracted with n-hexane, and organic phases removed and dried under argon. The dried organic phases were then separately dissolved in ethanol and aliquots were analyzed on a normal phase silica HPLC column developed with n-hexane containing 4% dioxane at 1 ml per minute. See Saari et al . J. Biol. Chem. 257:13329-13333 (1982) . Effluent was monitored at 330 nm. Under these conditions, 11-cis-retinaldehyde and ll-cis retinol eluted at 7 minutes and 22.5 minutes, respectively, and all-trans-retinaldehyde and all-trans retinol eluted at 8 minutes and 23 minutes, respectively. As indicated in FIG. 8B, the aforementioned HPLC analysis shows that fractions from transfected cells containing p32 expressed 11-cis-retinol dehydrogenase protein which was active in the presence of NAD+, as indicated by the formation of 11-cis-retinaldehyde. A second peak in the chromatogram is all-trans retinaldehyde; however, control incubations with ll-cis retinaldehyde, in the absence of cellular membranes, show that, under the test procedure employed, a large amount of ll-cis retinaldehyde isomerizes to all-trans retinaldehyde. This indicates that the appearance of all-trans retinaldehyde is due to its generation during the incubation process used and extraction procedures, and is not an enzymatic reaction product. Further, incubations with all-trans retinol with cells containing p32 verify the stereo specificity of the enzyme, as no significant formation of all-trans retinaldehyde is detected. As shown in FIG. 8C, p32 is not enzymatically active in the presence of cofactor NADP. In FIG. 8D, assays of the control cells not expressing p32 show that these do not oxidize 11-cis-retinol into 11- cis-retinaldehyde . Therefore, the above shows conclusively that p32 is a stereo specific 11-cis-retinol dehydrogenase, which relies on NAD+ as its cofactor. Example 11 Following the work described supra. u.sing bovine materials, additional experiments were carried out to isolate and to clone a human sequence. A cDNA library from human eye, in λgtll was purchased from a commercial supplier (i.e., Clontech) . The bovine cDNA described supra, i.e., SEQ ID NO: 10, was used as a probe. The cDNA was 32 [P] dCTP labelled by random priming to a high specific activity (about 10 9 cpm/μg of DNA) . The labelled bovine cDNA was then used to probe the human cDNA library. Conditions were as follows: hybridization in 6XSSC, 0.5% SDS, 5X Denhardt' s solution, 25% formamide, at 68°C, with 100 μg/ml of salmon sperm DNA, followed by four washes of 2XSSC, 0.5% SDS, at 65°C, for 30 minutes each, and then a final wash at 2xSSC at 42°C for 30 minutes . When a positive cDNA was found, the insert (i.e., the cDNA) , was excised following the manufacturer's instructions, and then subcloned into the commercially available vector pBluescript . The sequence of the insert was then determined, using well known methods. The sequence of 1128 nucleotides is set forth at SEQ ID NO: 14. The corresponding amino acid sequence of 318 residues is se forth in SEQ ID NO: 15. Example 12 In further experiments, the information described in example 11, supra, was used to study and to analyze bovine neuroretina and murine 10 day embryos. Murine embryos were used because, apart from the general usefulness of the system for studying developmental biology, retinol dehydrogenases are extremely active in development. The model is extrapolatable to human development . RNA (5-10μg) , was isolated from bovine neuroretinas, or from murine 10 day embryos, using well known techniques. The RNA was mixed in 4μl of 5x AMVRT buffer, together with 4μl of dNTPs from 5mM stock solutions, 2μl of oligo dT (18mer, at a final concentration of lOμM) , together with 0.5μl RNAse inhibitor, and 2μl of avian myelostosis virus reverse transcriptase (10U) . The final volume was 20 μl . This resulting mixture was incubated at 42°C for 30 minutes, and then left on ice until used. PCR was then carried out. In the PCR, two μl of cDNA were used. Primers were designed on the basis of the deduced amino acid sequence for bovine cDNA set forth supra. The following conserved amino acid sequences were noted: A) Cys Asp Ser Gly Phe Gly B) Pro Gly Trp Asp Ala C) Glu Ala Phe Ser Asp D) His Pro Arg Thr "A" corresponds to amino acids 36-41 of SEQ ID NO: 12. "B" is found at amino acids 283-287 of this sequence. "C" is found at positions 183-187, and "D" at positions 276- 279. "Conserved" as used herein refers to conservation between the deduced sequence, the sequence for liver RDH shown by Chai, et al . J. Biol. Chem 270: 3900-3904 (1995) , incorporated by reference in its entirety, and Simon, et al, J. Biol. Chem 270: 1107-1112 (1995) , also incorporated by reference. Degenerate oligomers were prepared. In a first set of PCR experiments, degenerate oligos based upon A and B were used as primers, i.e. : 5'- A C G T G A A T T C T G Y G A Y T C N G G N W T Y G G - 3' (SEQ ID NO:16) 5'- A C G T G A A T T C T T N G C R T C C C C A N C C - 3' (SEQ ID NO:17) as forward and reverse primers respectively. The primers were mixed with the two μl of cDNA discussed supra. Conditions were 1 minute of denaturation at 94°C, 1 minute of annealing at 50°C, and two minutes at 72°C, for elongation. This constituted 1 cycle. Twenty-five cycles were carried out . Following the first PCR. 5μl samples of PCR product were combined with primers based upon "C" and "D, " i.e. : 5'- A C G T G A A T T C G A R G C N T T Y T C N G A - 3' (SEQ ID NO:18) 5'- A C G T G A A T T C C G N G T N C K N G G R T G - 3' (SEQ ID N0:19) as forward and reverse primers, respectively. Conditions were exactly as used in the first set of experiments, except that the annealing temperature was 55°C. Reaction products were analyzed on 1.5% agarose gels with ethidium bromide. The assumption was that the amplification products should be about 300 base pairs in length. As such, any 300 base pair bands visualized confirmed that the PCR protocol generated products of appropriate size. The experiments were repeated, using 1% low melting point agarose gels, and the PCR products were eluted therefrom. The isolated products were reamplified, using the same protocols, and were cloned into plasmids (TA cloning kit, Invitrogen) . The plasmid DNA was prepared from transformants using standard protocols, and then analyzed by restriction digestion, using EcoRI. Any inserts of about 300 base pairs were analyzed further, using vector specific primers. The PCR products are presented in SEQ ID NOS: 20-23 with deduced amino acid sequences being presented as SEQ ID NOS: 24-27. SEQ ID NOS: 20 and 24 correspond to bovine sequences, while all others are murine sequences. In these nucleotide sequences, the first base ("C") is an artifact of the experiment, resulting from cleavage by a restriction endonuclease . Hence, one begins with the second nucleotide base in determining the deduced amino acid sequence . Further, note that sequences corresponding to the degenerate oligos, which would normally be included at the 5' and 3' termini, are not included. Example 13 The PCR product set forth in SEQ ID NO: 19 was then πserl i fιιτthpτ probing exper ent-?.. A murine 8.5 day cDNA library (in λgtlO) , was screened, using randomly labelled SEQ ID NO: 22, where the hybridization took place in 6XSSC, 0.5% SDS, 5x Denhardts's solution, 50% formamide at 42°C, with 100 μg/ml of salmon sperm DNA, followed by one wash at 2XSSC, 0.5% SDS at 50°C for 30 minutes. A positive cDNA clone was identified, subcloned into pBluescript, and sequenced. The nucleotide sequence, and deduced amino acid sequence, are set forth as SEQ ID NOS: 28 and 29. Example 14 Following the work described, supra, the human cDNA was used to probe a human genomic library. The probe was prepared by PCR and randomly labelled as described supra. The primers used in the PCR were derived from the cDNA sequence of SEQ ID NO: 11 and were as follows: Forward primer: 5'- G C T T C G G G C G C T G T A G T A-3' (SEQ ID NO:30) and Reverse Primer : 5' - A A A A C A A T C T C T T G C T G G A A-3" (SEQ ID NO: 31) PCR was carried out by denaturing at 95°C, followed by annealing at 55°C, and elongation at 72°C. 2-5U of Taq polymerase and 0.2μM of each primer were used. Thirty cycles were carried out . The amplified fragment of 1056bp was isolated, following agarose gel electrophoresis analysis and cloned into vector PCR (commercially available from Invitrogen) . This probe was used to screen a human genomic library in λFXII vector, from Stratagene. The manufacturer's instructions were followed to screen approximately lxlO 6 plaque forming units. 10 6 cpm/ml of hybridization solution was used. Hybridization was carried out overnight with SxSS , 0.5% SDS, 5 x Denhardt ' s solution, 50% formamide at 42°C, with lOOμg/ml of salmon sperm DNA, followed by one wash at 1 x SSC, 0.1% SDS at 50°C and a final wash at 0.5 x SSC, 0.1% SDS at 65°C. Each wash was for 30 minutes. Several positive plaques were isolated, rescreened, and λDNA prepared, using the glycerol step gradient method described by Sambrook et al . Molecular Cloning, A Laboratory Manual (2d edition, 1989) , incorporated by reference. The isolated genomic clones were sequenced by analyzing fragments obtained following PCR reactions, using 100 mg of genomic λ clones per reaction as templates. To carry out the PCR, different primers, derived from the cDNA sequence of SEQ ID NO:11 were used in two PCR reactions, numbered ' one ' and ' two '. Specifically, the primers used in PCR reaction one were SEQ ID NO:30, supra (forward primer) and 5'-C T C A G G C T G T C A G A G A A G G C C T-3' (SEQ ID NO: 32) (reverse primer) The primers used in PCR reaction two were 5'-G A C G A T T T C C A G C G G G T G C-3' (SEQ ID NO:33) (forward primer) and SEQ ID NO: 31, supra PCR was carried out by denaturing at 95°C, followed by annealing at 55°C and elongation at 72°C. 2-5U of Taq polymerase and 0.2μM of each primer was used. Thirty cycles were carried out. The amplified fragments from reactions one and two, were 2.2kb and 2.5kb respectively. Each fragment was cloned into vector PCR commercially available from Invitrogen. Sequence analysis of the cloned fragments using vector specific primers or internal primers, permitted identification of exon-intron boundaries. The structure of the gene is presented in figure 9. Example 15 Studies were carried out to identify the location of the gene on chromosomes. To do this, high molecular weight DNA was isolated from human leuckoytes, Chinese hamster cells, murine liver cells, and from hamster/human and mouse/human somatic hybrid cell lines. These hybrid cell lines each retained one human chromosome, as well as rodent genomes. The isolated DNA was digested with Hind III, fractionated on agarose gel via electrophoresis, and then transferred to a nylon filter. These were then probed, using the human cDNA described supra, labelled as described supra. Slides of chromosomes were prepared from lymphocyte cultures, using art recognized techniques. The λDNA from 3 genomic clones were mixed and labelled with biotinylated 16-dUTP, by Nick translation. A centromere specific probe for human chromosome 12 centromere (obtained from the ATCC, under Accession Number D12Z1) , was labelled with fluoro- red-dUTP, following the manufacturer's instructions. Pre- annealing of the probes, pretreatment of the slides, hybridization conditions, signal amplification, and detection, were in accordance with well known techniques. Chromosomes were counter-stained with 4,6 diamino-2-phenyl indole (DAPI) , and signal was visualized using a fluorescence microscope. Analysis of all of these data indicated that the gene for human ll-cis RDH spans more than 4 kilobases, and is divided into 4 coding exons, which range from 165 to 342 base pairs in length. Further, an exon was found in the 5 untranslated region, and the length of the last coding exon has not been established. Introns range in size from 250 base pairs to 1.9 kilobases. Figure 9 shows this schematically. Study of exon/intron boundaries showed that all splice donor and acceptor sites follow the well known, canonical GT/AG rule. The Initiation codon and the conserved cofactor binding site are encoded by exon 7 , while the active site, with invariant tyrosine residue, is encoded by exon 3. The gene for human ll-cis RDH maps to chromosome 12ql3-14. Example 16 The work set forth in example 12 was extended, using the nucleic acid molecules set forth in SEQ ID NOS: 21 and 22. A commercially available source of murine, multiple tissue Northern blots was used. Specifically, the nucleic acid molecules set forth in SEQ ID NOS: 21 and 22 were labelled with 32 P, using standard methodologies. These labelled probes were then used to determine relative expression levels of transcript in murine tissue samples, using standard Northern blotting protocols. Blots were hybridized, overnight, at 42°C, using 50% formamide, 6xSSPE buffer, 0.5% SDS, 2xDenhardt's solution, 100 ug/ml salmon sperm DNA, and lxlO 6 cpm/ml of labelled probe. Blots were washed at room temperature, twice, for 30 minutes per wash, using 2xSSC and 0.1% SDS, followed by two further washes, at 50°C, in 0. lxSSC containing 0.1% SDS. Blots were exposed at -70°C, overnight, using intensifying screens, and Kodak film. Relative expression levels, by visual inspection were as follows: PROBE Tissue SEQ ID NO: 21 SEQ ID NO: 22 Heart Brain - ++ Spleen Lung Liver +++++ +++++ Skeletal Muscle Kidney +++ +++- Testis Example 17 In view of the results of example 16, murine liver was used in the experiments which are described in this example. A murine liver cDNA library was prepared in λZAP, using standard protocols. Probes, as described in example 16, supra, were used to screen the library. Specifically, manufacturer's instructions were followed for plating the library and preparing the filters. prehybridization was carried out at 42°C, in 50% formamide, 6xSSPE buffer, 2xDenhardt' s solution, 100 ug/ml salmon sperm DNA. The filters were then hybridized, using lxlO 6 cpm/ml of hybridization-solution. Following overnight hybridization, filters were washed twice, in 2xSSC containing 0.1% SDS, (30 minutes per wash, at 52°C) , followed by two, 20 minute washes in 0. lxSSC containing 0.1% SDS, at 52°C. Filters were then exposed, as described supra. Any positive clones were rescreened, twice, until all plaques on a plate were positive. Inserts from several, positive clones were subcloned into plasmid pBluescript SK(+) , using standard procedure by in vivo excision. Several of the resulting clone were sequenced. When SEQ ID NO: 21 was used as a probe, three different cDNAs were identified. These are presented as SEQ ID NOS: 32, 33 AND 34, herein. When SEQ ID NO: 22 was used, SEQ ID NO: 35 was found. Amino acid sequences deduced therefrom are presented as SEQ ID NOS: 36-39, respectively. Thus, as shown above, this invention provides a method for the isolation and characterization of a novel protein, p32, which associates with the p63 of RPE. The primary structure of p32 demonstrates that it has all the critical features of a functional short-chain alcohol dehydrogenase including a putative cofactor binding site and essential residues involved in the catalytic mech n sm, mely th^ almost invariant tyrosine containing sequence motif Y-X-X- X-K (Persson et al . , Eur. J. Biochem. 200:537-543 (1991)) . The restricted tissue expression and the abundance of p32 in RPE indicates that this protein carries out a function which is unique to the RPE. This possibility, and the fact that it forms a complex with p63 which previously has been shown to be a component of the retinoid uptake machinery in RPE-cells (Bavik, et al . , J. Biol. Chem. 267:23035-23042 (1992) ) , shows that the substrate for p32 is a retinoid. A major metabolic step in retinoid metabolism in RPE- cells is the conversion of ll-cis retinol to ll-cis retinaldehyde. Based on the results obtained hereinabove showing the restricted expression of p32 in the RPE, and the particular biochemical properties of this protein further investigation confirmed that p32 is in fact an 11- cis-retinol dehydrogenase, the enzyme which catalyzes this reaction. Thus, one aspect of the invention is the ability to produce recombinant 11-cis-retinal dehydrogenase. The recombinant enzyme can be used to produce 11-cis- retinaldehyde in levels higher, and in purer form, than would be available using standard biochemical methodologies. Thus, the isolated nucleic acid molecules of the invention, which include SEQ ID NO: 10, as well as those nucleic acid molecules which hybridize to SEQ ID NO: 10 under stringent conditions can be used in this context. By the term "stringent conditions" is meant hybridization in 6 X SSC, 0.5% SDS, 5 X Denhardt's solution at 68°C, with 100 ug/ml of salmon sperm DNA, and a final wash with 0.5- 1.0 X SSC at 50°C. The term is also used herein to refer to any set of parameters which are at least as stringent as those set forth above. As is well known, equally stringent conditions can be created by changing one parameter to make it less stringent, with another parameter being changed to increase its stringency. Thus, any nucleic acid molecule which fulfills the hybridization criteria set forth herein w l be expected to code for p3 or a 3? homolngije he enzyme may be produced in an in vitro system, such as the one described above, or via transfecting or transforming eukaryotic or prokaryotic cell lines, such as CHO and COS cells or bacterial strains such as E. coli or the yeast strain S. cervisiae with the nucleic acid molecules of the invention. In an especially preferred embodiment, the nucleic acid molecules are contained within an expression vector, operably linked to a promoter. Complementary DNA, or "cDNA" is preferred, but genomic DNA and mRNA can also be used. The identification of the p32, ll-cis retinol dehydrogenase, as a member of the short-chain alcohol dehydrogenase superfamily is important in view of the retinoid-metabolism which occurs in non-ocular tissues. Studies show that generation of all-trans retinoic acid from all-trans retinol is carried out in a two step process (Posch et al., Biochemistry 30:6224-6230 (1991)) . First, retinol is oxidized to retinal by a membrane bound retinol dehydrogenase. In a second step, the retinal is oxidized to retinoic acid. Thus, the oxidation of retinol into retinal, occurring in non-ocular tissues, is similar to the reaction carried out during synthesis of ll-cis retinal from ll-cis retinol in the visual cycle. In light of these similarities, it can be proposed that formation of all- trans retinal from all-trans retinol is carried out by an enzyme which is structurally similar to the p32 ll-cis retinol dehydrogenase isolated by this invention. These findings are surprising in contrast to presently held views as it is generally believed that this metabolic step is carried out by members of the medium chain alcohol dehydrogenases. See Duester, Alcohol Clin. Exp. Res. 15:568-572 (1991) ; Yang et al . , Alcohol Clin. Exp. Res. 17:496 (1993) and Zgombic-Knight et al. , J. Biol. Chem. 269:6790-6795 (1994) . Thus the identification and structural characterization of the p32 ll-cis retinol dehydrogenase, provided by this invention also provides a rp inυsly une ecte avenue for the solation a characterization of similar dehydrogenases involved in retinol metabolism is non-ocular tissues. The p32 protein and nucleic acid encoding therefor and other aspects of this invention are also useful in many other important applications. For example, as it has been shown that p32 is part of an oligomeric protein complex which functions as a membrane receptor for RBP in RPE- cells, the nucleic acid sequence coding for p32 can be used in a phenotypic/genic diagnostic analysis to determine retinoid accumulation, which can lead to retinitis pigmentosa. Additionally, as shown, p32 possesses 11-cis-retinol dehydrogenase activity, which catalyzes the conversion of ll-cis retinol to 11-cis-retinaldehyde, a major metabolic step in retinoid metabolism in RPE-cells carried out by a membrane bound dehydrogenase. Thus, retinoid accumulation may be directly or indirectly tied to the presence of p32 and/or its activation or inhibition, for example, its complex formation with the RBP receptor p63. In other applications the effect of potential retinoid drugs for treatment of various diseases on the 11-cis- retinal dehydrogenase activity of p32 may be assayed as such drugs may adversely effect the enzyme, and to thus determine which of the different drugs have limited or no adverse effect on enzyme activity. Examples of such diseases include those of the eye and also skin disorders such as psoriasis and acne. Certain cancers such as T-cell leukemias may also be tested by retinoid drugs and hence be candidates for assaying p32 activity. The various known functions of retinoids also suggests that various other retinoid linked pathological conditions may be diagnosed via assays for levels of the p63/p32 receptor complex associated with a particular retinol binding protein. Art recognized techniques may be used, such a immunoassays, and so forth, to determine whether p63/p32 receptor complex levels are too low or too high -- i.e., are at variance with a normal level. Further, as p32 complexes with the p63 component of the retinoid uptake machinery in RPE cells, it may also be used in a therapeutic context, as it is well known that soluble receptors may be used to prevent binding of a protein to its membrane-linked receptor. Thus, a subject characterized by enhanced levels of production of retinol binding protein may be treated via administering an amount of soluble receptor complex or antibody sufficient to inhibit binding of the retinol binding protein or other related molecule to its target, namely, an inhibitor of p32's retinol dehydrogenase activity. Other aspects of the invention will be clear to the skilled artisan and need not be repeated here. In yet another application, monoclonal and polyclonal antibodies to p32 can be generated, which are useful, inter alia, in monitoring the instance of pathological conditions characterized by aberrant levels of a receptor for retinol binding protein, by binding analysis of the antibody with body fluid or tissue samples. The generation of antibodies to p32 can be accomplished, for example, by using the procedure set out in Bavik et al . , J. Biol. Chem. 268:20540-20546 (1993) for the generation of antibodies to p63, including mAb A52. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention. (1) GENERAL INFORMATION: (i) APPLICANTS: ERIKSSON ET AL. (ii) TITLE OF INVENTION: ISOLATED NUCLEIC ACID MOLECULE WHICH CODES FOR A 32 KDA PROTEIN HAVING 11-CIS RETINOL DEHYDROGENASE ACTIVITY, AND WHICH ASSOCIATES WITH P63, A PORTION OF A RETINOL BINDING PROTEIN RECEPTOR (iii) NUMBER OF SEQUENCES: 39 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Felfe _ Lynch (B) STREET: 805 Third Avenue (C) CITY: New York City (D) STATE: New Yoxk (F) ZIP: 10022 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette, 3.5 inch, 144 kb storage (B) COMPUTER: IBM (C) OPERATING SYSTEM: PC-DOS (D) SOFTWARE: Wordperfect (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/562,114 (B) FILING DATE: 22-November-1995 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/375,962 (B) FILING DATE: 20-January-1995 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/258,418 (B) FILING DATE: 10-June-1994 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Hanson, Norman D (B) REGISTRATION NUMBER: 30,946 (C) REFERENCE/DOCKET NUMBER: LUD 5372.3-PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 688-9200 (B) TELEFAX: (212) 838-3884 INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Leu Val Glu Ala Val Leu Ala Glu Val Leu Pro Lys Pro Ala Gin Thr 5 10 15 Val Ala INFORMATION FOR SEQ ID NO: 2 : (1) i-KQUKNCE C_iAkAC-.-_-_-i.-iCb : (A) LENGTH: 8 ammo acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2 Tyr Ser Pro Gly Trp Asp Ala Lys 5 INFORMATION FOR SEQ ID NO: 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE : amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Thr Pro Val Thr Asn Leu Glu Thr Leu Glu Asp Thr Leu Gin Ala 5 10 15 INFORMATION FOR SEQ ID NO: 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Asp Val Ala Pro Phe Gly Val 5 INFORMATION FOR SEQ ID NO: 5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Leu His Thr Thr Leu Leu Asp Val Thr Asp Pro Gin Ser lie 5 10 INFORMATION FOR SEQ ID NO: 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE:nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: ACGTGAATTC TNGTNGARGC NGT 23 INFORMATION FOR SEQ ID NO: 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TϊPΞ-. nucleic ctcid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: ACGTGAATTC ACNGTYTGNG CNGGYTT 27 INFORMATION FOR SEQ ID NO: 8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: ACGTGAATTC CCNGTNACNA AYYT 24 INFORMATION FOR SEQ ID NO: 9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: ACGTGAATTC GCYTGNARNG TRTCYTC 27 INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1122 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: p32;ll-cis retinol dehydrogenase (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: AGCTTTCCCC TGAGGAGGTC ACCTGGGCTC CAGCC ATG TGG CTG CCT CTG CAG 53 Met Trp Leu Pro Leu Leu 5 TGC CTG CTG CTG GGT GTC TTG CTC TGG GCA GCA CTG TGG TTG CTC AGG 101 Leu Gly Val Leu Leu Trp Ala Ala Leu Trp Leu Leu Arg Asp Arg Gin 10 15 20 GAC CGG CCA GCC AGC GAT GCC TTT ATC TTC ATC ACC GGC TGT GAC TCG 149 Cys Leu Pro Ala Ser Asp Ala Phe lie Phe lie Thr Gly Cys Asp Ser 25 30 35 GGC TTT GGG CGG CTC CTT GCT CTG AGG CTG GAC CAG AGA GGC TTC CGA 197 Gly Phe Gly Arg Leu Leu Ala Leu Arg Leu Asp Gin Arg Gly Phe Arg 40 45 50 GTA CTG GCC AGC TGC CTG ACA CCC TCG GGG GCG GAG GAC CTC CAG CGG 245 Val Leu Ala Ser Cys Leu Thr Pro Ser Gly Ala Glu Asp Leu Gin Arg 55 60 65 70 GTC GCC TCC TCC CGC CTC CAC ACC ACC CTG CTG GAT GTC ACA GAT CCC 293 Val Ala Ser Ser Arg Leu His Thr Thr Leu Leu Asp Val Thr Asp Pro 75 80 85 CAG AGC ATC CGG CAG GCA GTC AAG TGG GTG GAA ACG CAT GTT GGG GAA 341 Gin Ser lie Arg Gin Ala Val Lys Trp Val Glu Thr His Val Gly Glu 90 95 100 GCA GGG CTT TTT GGT CTG GTG AAT AAT GCT GGT GTG GCT GGC ATC ATT 389 Ala Gly Leu Phe Gly Leu Val Asn Asn Ala Gly Val Ala Gly lie lie 105 110 115 GGT CCC ACC CCA TGG CAG ACG CGG GAG GAC TTC CAG CGG GTG CTG AAT 437 Gly Pro Thr Pro Trp Gin Thr Arg Glu Asp Phe Gin Arg Val Leu Asn 120 125 130 GTG AAC ACG CTG GGT CCC ATC GGG GTC ACC CTC GCC CTG CTG CCC CTG 485 Val Asn Thr Leu Gly Pro lie Gly Val Thr Leu Ala Leu Leu Pro Leu 135 140 145 150 CTG CTG CAG GCC CGG GGC CGA GTG ATC AAC ATC ACC AGT GTC CTT GGC 533 Leu Leu Gin Ala Arg Gly Arg Val lie Asn He Thr Ser Val Leu Gly 155 160 165 CGT CTG GCA GCC AAT GGA GGG GGC TAC TGC GTC TCC AAG TTT GGC CTG 581 Arg Leu Ala Ala Asn Gly Gly Gly Tyr Cys Val Ser Lys Phe Gly Leu 170 175 180 GAG GCC TTC TCT GAC AGC CTG AGG CGA GAT GTG GCT CCT TTT GGG GTA 629 Glu Ala Phe Ser Asp Ser Leu Arg Arg Asp Val Ala Pro Phe Gly Val 185 190 195 CGG GTC TCT ATC GTG GAA CCT GGC TTC TTC CGA ACC CCT GTG ACA AAC 677 Arg Val Ser He Val Glu Pro Gly Phe Phe Arg Thr Pro Val Thr Asn 200 205 210 CTG GAA ACT TTG GAG GAC ACC CTG CAG GCC TGC TGG GCA CGG CTG CCT 725 Leu Glu Thr Leu Glu Asp Thr Leu Gin Ala Cys Trp Ala Arg Leu Pro 215 220 225 230 CCA GCC ACA CAG GCC CTC TAT GGG GAG GCC TTC CTC ACC AAA TAC CTG 773 Pro Ala Thr Gin Ala Leu Tyr Gly Glu Ala Phe Leu Thr Lys Tyr Leu 235 240 245 AGA GTG CAG CAA CGT ATC ATG AAC ATG ATC TGT GAT CCG GAC CTG GCC 821 Arg Val Gin Gin Arg He Met Asn Met He Cys Asp Pro Asp Leu Ala 250 255 260 AAG GTG AGC AGG TGC CTG GAG CAT GCC CTA ACT GCC CGT CAC CCC AGA 869 Lys Val Ser Arg Cys Leu Glu His Ala Leu Thr Ala Arg His Pro Arg 265 270 275 ACC CGC TAC AGC CCA GGC TGG GAT GCC AAG CTG CTC TGG TTG CCA GCC 917 Thr Arg Tyr Ser Pro Gly Trp Asp Ala Lys Leu Leu Trp Leu Pro Ala 280 285 290 TCC TAC TTG CCA GCC AGG CTG GTG GAT GCT GTG CTC GCC TGG GTC CTT 965 Ser Tyr Leu Pro Ala Arg Leu Val Asp Ala Val Leu Ala Trp Val Leu 295 300 305 310 CCC AAG CCT GCC CAG ACA GTC TAC TAA ATCCAGCCCT CCAGCAAAAG 1012 Pro Lys Pro Ala Gin Thr Val Tyr 315 ATGGTTGTTC AAGGCAAGGA CTCTGATTTA TTCTGTCCCC TACCCTGGTA CTGCCTGGTG 1072 TGTGGCATAA AACAGTCACT CAATAAATGT ATTATTCAAA ACAAAAAAAA 1122 INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 amino acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (n) MOLECULE TYPE: protem (ix) FEATURE: (A) NAME/KEY: Rat D-b-hydroxybutyrate dehydrogenase (rBDH) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met Met Leu Ala Ala Arg Leu Ser Arg Pro Leu Ser Gin Leu Pro Gly 5 10 15 Lys Ala Leu Ser Val Cys Asp Arg Glu Asn Gly Thr Arg His Thr Leu 20 25 30 Leu Phe Tyr Pro Ala Ser Phe Ser Pro Asp Thr Arg Arg Thr Tyr Thr 35 40 45 Ser Gin Ala Asp Ala Ala Ser Gly Lys Ala Val Leu Val Thr Gly Cys 50 55 60 Asp Ser Gly Phe Gly Phe Ser Leu Ala Lys His Leu His Ser Lys Gly 65 70 75 80 Phe Leu Val Phe Ala Gly Cys Leu Leu Lys Glu Gin Gly Asp Ala Gly 85 90 95 Val Arg Glu Leu Asp Ser Leu Lys Ser Asp Arg Leu Arg Thr He Gin 100 105 110 Leu Asn Val Cys Asn Ser Glu Glu Val Glu Lys Ala Val Glu Thr Val 115 120 125 Arg Ser Gly Leu Lys Asp Pro Glu Lys Gly Met Trp Gly Leu Val Asn 130 135 140 Asn Ala Gly He Ser Thr Phe Gly Glu Val Glu Phe Thr Ser Met Glu 145 150 155 160 Thr Tyr Lys Glu Val Ala Glu Val Asn Leu Trp Gly Thr Val Arg Thr 165 170 175 Thr Lys Ser Phe Leu Pro Leu Leu Arg Arg Ala Lys Gly Arg Val Val 180 185 190 Asn He Ser Ser Met Leu Gly Arg Met Ala Asn Pro Ala Arg Ser Pro 195 200 205 Tyr Cys He Thr Lys Phe Gly Val Glu Ala Phe Ser Asp Cys Leu Arg 210 215 220 Tyr Glu Met His Pro Leu Gly Val Lys Val Ser Val Val Glu Pro Gly 225 230 235 240 Asn Phe He Ala Ala Thr Ser Leu Tyr Ser Pro Glu Arg He Gin Ala 245 250 255 He Ala Lys Lys Met Trp Asp Glu Leu Pro Glu Val Val Arg Lys Asp 260 265 270 Tyr Gly Lys Lys Tyr Phe Λcp Glu Ly He Λla Ly Met Cl Thr Tyr 275 280 285 Cys Asn Ser Gly Ser Thr Asp Thr Ser Ser Val He Asn Ala Val Thr 290 295 300 His Ala Leu Thr Ala Ala Thr Pro Tyr Thr Arg Tyr His Pro Met Asp 305 310 315 320 Tyr Tyr Trp Trp Leu Arg Met Gin Val Met Thr His Phe Pro Gly Ala 325 330 335 He Ser Asp Lys He Tyr He His 340 INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Human estradiol 17-b dehydrogenase (hEDH) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Ala Arg Thr Val Val Leu He Thr Gly Cys Ser Ser Gly He Gly Leu 5 10 15 His Leu Ala Val Arg Leu Ala Ser Asp Pro Ser Gin Ser Phe Lys Val 20 25 30 Tyr Ala Thr Leu Arg Asp Leu Lys Thr Gin Gly Arg Leu Trp Glu Ala 35 40 45 Ala Arg Ala Leu Ala Cys Pro Pro Gly Ser Leu Glu Thr Leu Gin Leu 50 55 60 Asp Val Arg Asp Ser Lys Ser Val Ala Ala Ala Arg Glu Arg Val Thr 65 70 75 80 Glu Gly Arg Val Asp Val Leu Val Cys Asn Ala Gly Leu Gly Leu Leu 85 90 95 Gly Pro Leu Glu Ala Leu Gly Glu Asp Ala Val Ala Ser Val Leu Asp 100 105 110 Val Asn Val Val Gly Thr Val Arg Met Leu Gin Ala Phe Leu Pro Asp 115 120 125 Met Lys Arg Arg Gly Ser Gly Arg Val Leu Val Thr Gly Ser Val Gly 130 135 140 Gly Leu Met Gly Leu Pro Phe Asn Asp Val Tyr Cys Ala Ser Lys Phe 145 150 155 160 Ala Leu Glu Gly Leu Cys Glu Ser Leu Ala Val Leu Leu Leu Pro Phe 165 170 175 Gly Val His Leu Ser Leu He Glu Cys Gly Pro Val His Thr Ala Phe 180 185 190 Met Glu L/G Val Leu Gly Ser Pre Glu Clu Vαl Leu Λep Λrg Thr Λεp 195 200 205 He His Thr Phe His Arg Phe Tyr Gin Tyr Leu Ala His Ser Lys Gin 210 215 220 Val Phe Arg Glu Ala Ala Gin Asn Pro Glu Glu Val Ala Glu Val Phe 225 230 235 240 Leu Thr Ala Leu Arg Ala Pro Lys Pro Thr Leu Arg Tyr Phe Thr Thr 245 250 255 Glu Arg Phe Leu Pro Leu Leu Arg Met Arg Leu Asp Asp Pro Ser Gly 260 265 270 Ser Asn Tyr Val Thr Ala Met His Arg Glu Val Phe Gly Asp Val Pro 275 280 285 Ala Lys Ala Glu Ala Gly Ala Glu Ala Gly Gly Gly Ala Gly Pro Gly 290 295 300 Ala Glu Asp Glu Ala Gly Arg Ser Ala Val Gly Asp Pro Glu Leu Gly 305 310 315 320 Asp Pro Pro Ala Ala Pro Gin 325 INFORMATION FOR SEQ ID NO: 13 (i) SEQUENCE CHARACTERISTICS- (A) LENGTH: 244 am o acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY:E. coli 3-oxoacyl [acyl carrier protein] reductase (FABG) (xi) SEQUENCE DESCRIPTION: SEQ ID NO.13 : Met Asn Phe Glu Gly Lys He Ala Leu Val Thr Gly Ala Ser Arg Gly 5 10 15 He Gly Arg Ala He Ala Glu Thr Leu Ala Ala Arg Gly Gly Lys Val 20 25 30 He Gly Thr Ala Thr Ser Glu Asn Gly Ala Gin Ala He Ser Asp Tyr 35 40 45 Leu Gly Ala Asn Gly Lys Gly Leu Met Leu Asn Val Thr Asp Pro Ala 50 55 60 Ser He Glu Ser Val Leu Glu Lys He Arg Ala Glu Phe Gly Glu Val 65 70 75 80 Asp He Leu Val Asn Asn Ala Gly He Thr Arg Asp Asn Leu Leu Met 85 90 95 Arg Met Lys Asp Glu Glu Trp Asn Asp He He Glu Thr Asn Leu Ser 100 105 110 Ser Val Phe Arg Leu Ser Lys Ala Val Met Arg Ala Met Met Lys Lys 115 120 125 Ary Hit. Gly A_.y lie He Tin. He Gly Ser Vαl Val Gly Tlir Met Gly 130 135 140 Asn Gly Gly Gin Ala Asn Tyr Ala Ala Ala Lys Ala Gly Leu He Gly 145 150 155 160 Phe Ser Lys Ser Leu Ala Arg Glu Val Ala Ser Arg Gly He Thr Val 165 170 175 Asn Val Val Ala Pro Gly Phe He Glu Thr Asp Met Thr Arg Ala Leu 180 185 190 Ser Asp Asp Gin Arg Ala Gly He Leu Ala Gin Val Pro Ala Gly Arg 195 200 205 Leu Gly Gly Ala Gin Glu He Ala Asn Ala Val Ala Phe Leu Ala Ser 210 215 220 Asp Glu Ala Ala Tyr He Thr Gly Glu Thr Leu His Val Asn Gly Gly 225 230 235 240 Met Tyr Met Val INFORMATION FOR SEQ ID NO: 14 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1128 base pairs (B) TYPE:nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: human ll-cis retinol dehydrogenase (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: TAAGCTTCGG GCGCTGTAGT ACCTGCCAGC TTTCGCCACA GGAGGCTGCC 50 ACCTGTAGGT CACTTGGGCT CCAGCTATGT GGCTGCCTCT TCTGCTGGGT 100 GCCTTACTCT GGGCAGTGCT GTGGTTGCTC AGGGACCGGC AGAGCCTGCC 150 CGCCAGCAAT GCCTTTGTCT TCATCACCGG CTGTGACTCA GGCTTTGGGC 200 GCCTTCTGGC ACTGCAGCTG GACCAGAGAG GCTTCCGAGT CCTGGCCAGC 250 TGCCTGACCC CCTCCGGGGC CGAGGACCTG CAGCGGGTGG CCTCCTCCCG 300 CCTCCACACC ACCCTGTTGG ATATCACTGA TCCCCAGAGC GTCCAGCAGG 350 CAGCCAAGTG GGTGGAGATG CACGTTAAGG AAGCAGGGCT TTTTGGTCTG 400 GTGAATAATG CTGGTGTGGC TGGTATCATC GGACCCACAC CATGGCTGAC 450 CCGGGACGAT TTCCAGCGGG TGCTGAATGT GAACACAATG GGTCCCATCG 500 GGGTCACCCT TGCCCTGCTG CCTCTGCTGC AGCAAGCCCG GGGCCGGGTG 550 ATCAACATCA CCAGCGTCCT GGGTCGCCTG GCAGCCAATG GTGGGGGCTA 600 CTGTGTCTCC AAATTTGGCC TGGAGGCCTT CTCTGACAGC CTGAGGCGGG 650 ATGTAGCTCA TTTTGGGATA CGAGTCTCCA TCGTGGAGCC TGGCTTCTTC 700 CGAACCCCTG TGACCAACCT GGAGAGTCTG GAGAAAACCC TGCAGGCCTG 750 CTGGGCACGG CTGCCTCCTG CCACACAGGC CCACTATGGG GGGGCCTTCC 800 TCACCAAGTA CCTGAAAATG CAACAGCGCA TCATGAACCT GATCTGTGAC 850 CCGGACCTAA CCAAGGTGAG CCGATGCCTG GAGCATGCCC TGACTGCTCG 900 ACACCCCCGA ACCCGCTACA GCCCAGGTTG GGATGCCAAG CTGCTCTGGC 950 TGCCTGCCTC CTACCTGCCA GCCAGCCTGG TGGATGCTGT GCTCACCTGG 1000 GTCCTTCCCA AGCCTGCCCA AGCAGTCTAC TGAATCCAGC CTTCCAGCAA 1050 GAGATTGTTT TTCAAGGACA AGGACTTTGA TTTATTTCTG CCCCCACCCT 1100 GGTACTGCCT GGTGCCTGCC ACAAAATA 1128 INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: human ll-cis retinol dehydrogenase (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: Met Trp Leu Pro Leu Leu Leu Gly Ala Leu Leu Trp Ala Val Leu Trp 5 10 15 Leu Leu Arg Asp Arg Gin Ser Leu Pro Ala Ser Asn Ala Phe Val Phe 20 25 30 He Thr Gly Cys Asp Ser Gly Phe Gly Arg Leu Leu Ala Leu Gin Leu 35 40 45 Asp Gin Arg Gly Phe Arg Val Leu Ala Ser Cys Leu Thr Pro Ser Gly 50 55 60 Ala Glu Asp Leu Gin Arg Val Ala Ser Ser Arg Leu His Thr Thr Leu 65 70 75 80 Leu Asp He Thr Asp Pro Gin Ser Val Gin Gin Ala Ala Lys Trp Val 85 90 95 Glu Met His Val Lys Glu Ala Gly Leu Phe Gly Leu Val Asn Asn Ala 100 105 110 Gly Val Ala Gly He He Gly Pro Thr Pro Trp Leu Thr Arg Asp Asp 115 120 125 Phe Gin Arg Val Leu Asn Val Asn Thr Met Gly Pro He Gly Val Thr 130 135 140 Leu Ala Leu Leu Pro Leu Leu Gin Gin Ala Arg Gly Arg Val He Asn 145 150 155 160 He Thr Ser Val Leu Gly Arg Leu Ala Ala Asn Gly Gly Gly Tyr Cys 165 170 175 Val Ser Lys Phe Gly Leu Glu Ala Phe Ser Asp Ser Leu Arg Arg Asp 180 185 190 Val Ala His Phe Gly He Arg Val Ser He Val Glu Pro Gly Phe Phe 195 200 205 Arg Thr Pro Val Thr Asn Leu Glu Ser Leu Glu Lys Thr Leu Gin Ala 210 215 220 Cys Trp Ala Arg Leu Pro Pro Ala Thr Gin Ala His Tyr Gly Gly Ala 225 230 235 240 Phe Leu Thr Lys Tyr Leu Lys Met Gin Gin Arg He Met Asn Leu He 245 250 255 Cys Asp Pro Asp Leu Thr Lys Val Ser Arg Cys Leu Glu His Ala Leu 260 265 270 Thr Ala Arg His Pro Arg Thr Arg Tyr Ser Pro Gly Trp Asp Ala Lys 275 280 285 Leu Leu Trp Leu Pro Ala Ser Tyr Leu Pro Ala Ser Leu Val Asp Ala 290 295 300 Val Leu Thr Trp Val Leu Pro Lys Pro Ala Gin Ala Val Tyr 305 310 315 INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE:nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: PCR primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: ACGTGAATTC TGYGAYTCNG GNWTYGG 27 INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE:nucleιc acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: PCR primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ACGTGAATTC TTNGCRTCCC CANCC 25 INFORMATION FOR SEQ ID NO:18: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE:nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: PCR primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: ACGTGAATTC GARGCNTTYT CNGA 24 INFORMATION FOR SEQ ID NO.19 (l) SEQUENCE CHARACTERISTICS (A) LENGTH 24 base pairs (B) TYPE.nucleic acid (D) TOPOLOGY linear (nl MOLECULE TYPE nucleic acid (ix) FEATURE (A) NAME/KEY PCR primer (xi) SEQUENCE DESCRIPTION SEQ ID NO 19 ACGTGAATTC CGNGTNCKNG GRTG 24 INFORMATION FOR SEQ ID NO 20 ι SEQuEl.CE CKARACIΞklSIiCS (A) LENGTH 262 base pairs (B) TYPE nucleic acid (D) TOPOLOGY linear (ii) MOLECULE TYPE nucleic acid (ix) FEATURE (A) NAME/KEY PCR clone 194 (xi) SEQUENCE DESCRIPTION SEQ ID NO 20 CTCTCTCAGA AGGGAGCTCT CCTACTTCGG AGTGAAGGTG GCTATGATTG AGCCTGGTTA 60 CTTTGTTACC AATATGACCC AAGATGAGGG TTTTATTGGA TACCTCCAGG CATTGTGGAA 120 CCGGGCCAGC CCAGAGCTGA AAGAACTCTA TGGAGAAAAC TTCCCTGCTG ACTTCTTGAA 180 GACATTGAGT TTACTGAAAC CACGGTGGAC TCAGAATCTG TCCTTGGTGA CCGACTGCAT 240 GGAGCACGCC CTGACTGCCT GC 262 INFORMATION FOR SEQ ID NO 21 ( ) SEQUENCE CHARACTERISTICS (A) LENGTH 262 base pairs (B) TYPE nucleic acid (D) TOPOLOGY linear (n) MOLECULE TYPE nucleic acid (ix) FEATURE (A) NAME/KEY PCR clone 207 (xi) SEQUENCE DESCRIPTION SEQ ID NO 21 CTCCCTCAGG AGGGGGCTCT CCTACTTTGG GGTGAAGGTG GCTATTATAG AGCCTGGCTT 60 CTTCCTGACC GGTGTGACCA GTAGTGCCAG ATTATGCTCA AATACCCAGA TGCTGTGGGA 120 CCAGACCAGC TCAGAAATCA GGGAGATCTA TGGCGAGAAG TACCTGGCAT CCTATCTGAA 180 AAGGCTAAAC GAATTGGACA AGAGGTGCAA CAAGGACCTG TCTTTGGTGA CTGACTGCAT 240 GGAGCATGCT CTGACTGCCT GC 262 INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 265 base pairs (B) TYPE:nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: PCR clone 200 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: CAGCCTGAGG CGGGACATGG CTCCGTTCGG AGTACAAGTC TCCATTGTGG AGCCTGGCTT 60 CTTTCGAACC CCTGTGACCA ACCTGGAGAG TCTGGAGAGC ACCCTGAAGG CTTGTTGGGC 120 Cuuo AuU-- _.TC TCTTCG ICC AGTACAGCGC CGCATCATGA ACCTGATCTG TGACCCAGAA CTAACGAAGG TGACCAGCTG 240 CCTGGAGCAT GCCCTGACTG CTCGC 265 INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 265 base pairs (B) TYPE:nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: PCR clone 215 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CAGCCTGAGG CGAGATGTGG CTCCTTTTGG GGTACGGGTC TCTATCGTGG AACCTGGCTT 60 CTTCCGAACC CCTGTGACAA ACCTGGAAAC TTTGGAGGGC ACCCTGCAGG CCTGCTGGGC 120 ACGGCTGCCT CCAGCCACAC AGGCCCTCTA TGGGGAGGCC TTCCTCACCA AATACCTGAG 180 AGTGCAGCAA CGTATCATGA ACATGATCTG TGATCCGGAC CTGGCCAAGG TGAGCAGGTG 240 CCTGGAGCAT GCCCTAACTG CCCGT 265 INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: PCR clone 194 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24 : Ser Leu Arg Arg Glu Leu Ser Tyr Phe Gly Val Lys Val Ala Met He 5 10 15 Glu Pro Gly Tyr Phe Val Thr Asn Met Thr Gin Asp Glu Gly Phe He 20 25 30 Gly Tyr Leu Gin Ala Leu Trp Asn Arg Ala Ser Pro Glu Leu Lys Glu 35 40 45 Leu Tyr Gly Glu Asn Phe Pro Ala Asp Phe Leu Lys Thr Leu Ser Leu 50 55 60 Leu Lys Pro Arg Trp Thr Gin Asn Leu Ser Leu Val Thr Asp Cys Met 65 70 75 80 Glu His Ala Leu Thr Ala Cys 85 INFORMATION FOR SEQ ID NO:25: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 ammo acids (B / TYPE . _.i-ij.l_t_ d__- (D) TOPOLOGY- linear Ui) MOLECULE TYPE: protein (i ) FEATURE: (A) NAME/KEY: PCR clone 207 (xi) SEQUENCE DESCRIPTION- SEQ ID NO:25: Ser Leu Arg Arg Gly Leu Ser Tyr Phe Gly Val Lys Val Ala He He 5 10 15 Glu Pro Gly Phe Phe Leu Thr Gly Val Thr Ser Ser Ala Arg Leu Cys 20 25 30 Ser Asn Thr Gin Met Leu Trp Asp Gin Thr Ser Ser Glu He Arg Glu 35 40 45 He Tyr Gly Glu Lys Tyr Leu Ala Ser Tyr Leu Lys Arg Leu Asn Glu 50 55 60 Leu Asp Lys Arg Cys Asn Lys Asp Leu Ser Leu Val Thr Asp Cys Met 65 70 75 80 Glu His Ala Leu Thr Ala Cys 85 INFORMATION FOR SEQ ID NO: 26 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH 88 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY: linear Ui) MOLECULE TYPE: protem Ux) FEATURE: (A) NAME/KEY: PCR clone 200 (x ) SEQUENCE DESCRIPTION: SEQ ID NO:26 Ser Leu Arg Arg Asp Met Ala Pro Phe Gly Val Gin Val Ser He Val 5 10 15 Glu Pro Gly Phe Phe Arg Thr Pro Val Thr Asn Leu Glu Ser Leu Glu 20 25 30 Ser Thr Leu Lys Ala Cys Trp Ala Arg Leu Pro Pro Ala He Gin Ala 35 40 45 His Tyr Gly Glu Ala Phe Leu Asp Thr His Leu Arg Val Gin Arg Arg 50 55 60 He Met Asn Leu He Cys Asp Pro Glu Leu Thr Lys Val Thr Ser Cys 65 70 75 80 Leu Glu His Ala Leu Thr Ala Arg 85 INFORMATION FOR SEQ ID NO:27: U) SEQUENCE CHARACTERISTICS: (A) LENGTH: 88 ammo acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (I ) FEATURE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27; Ser Leu Arg Arg Asp Val Ala Pro Phe Gly Val Arg Val Ser He Val 5 10 15 Glu Pro Gly Phe Phe Arg Thr Pro Val Thr Asn Leu Glu Thr Leu Glu 20 25 30 Gly Thr Leu Gin Ala Cys Trp Ala Arg Leu Pro Pro Ala Thr Gin Ala 35 40 45 Leu Tyr Gly Glu Ala Phe Leu Thr Lys Tyr Leu Arg Val Gin Gin Arg 50 55 60 He Met Asn Met He Cys Asp Pro Asp Leu Ala Lys Val Ser Arg Cys 65 70 75 80 Leu Glu His Ala Leu Thr Ala Arg 85 INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 563 base pairs (B) TYPE:nucleιc acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (ix) FEATURE: (A) NAME/KEY: clone ME207. (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: GAGGCGTTCT CGGACTCCCT CAGGAGGGGG CTCTCCTACT TTGGGGTGAA GGTGGCTATT 60 ATAGAGCCTG GCTTCTTCCT GACCGGTGTG ACCAGTAGTG CCAGATTATG CTCAAATACC 120 CAGATGCTGT GGGACCAGAC CAGCTCAGAA ATCAGGGAGA TCTATGGCGA GAAGTACCTG 180 GCATCCTATC TGAAAAGGCT AAACGAATTG GACAAGAGGT GCAACAAGGA CCTGTCTTTG 240 GTGACTGACT GCATGGAGCA TGCTCTGACT GCCTGCCACC CTCGCACGCG ATACTCAGCT 300 GGCTGGGATG CTAAGCTCTT CTACCTCCCC TTGAGCTACC TGCCTACCTT TCTTGTGGAT 360 GCCCTTCTCT ATTGGACTTC CCTGAAGCCT GAGAAAGCCC TCTGACGTGT TCACCTATGT 420 GCATACCTGG GGAGATGTAG GTAGAGTTTG AGAGAGAGAA TATTTAGGGG AAATTTGGAG 480 GGTTGAGGGA GGGAGTTTAT TACTCTGGGG TTCAGTCAAC ACACTTCATC TCATTAATTC 540 TCCTATGACA CTACTGAATA CTG 563 INFORMATION FOR SEQ ID NO:29. U) SEQUENCE CHARACTERISTICS: (A) LENGTH: 134 amino acids (B) TYPE, ammo acid (D) TOPOLOGY: linear Ui) MOLECULE TYPE: protein (i ) FEATURE: (A) NAME/KEY: clone ME207 (xi) SEQUENCE DESCRIPTION SEQ ID NO:29 Glu Ala Phe Ser Asp Ser Leu Arg Arg Gly Leu Ser Tyr Phe Gly Val 5 10 15 Lys Val Ala He He Glu Pro Gly Phe Phe Leu Thr Gly Val Thr Ser 20 25 30 Ser Ala Arg Leu Cys Ser Asn Thr Gin Met Leu Trp Asp Gin Thr Ser 35 40 45 Ser Glu He Arg Glu He Tyr Gly Glu Lys Tyr Leu Ala Ser Tyr Leu 50 55 60 Lys Arg Leu Asn Glu Leu Asp Lys Arg Cys Asn Lys Asp Leu Ser Leu 65 70 75 80 Val Thr Asp Cys Met Glu His Ala Leu Thr Ala Cys His Pro Arg Thr 85 90 95 Arg Tyr Ser Ala Gly Trp Asp Ala Lys Leu Phe Tyr Leu Pro Leu Ser 100 105 110 Tyr Leu Pro Thr Phe Leu Val Asp Ala Leu Leu Tyr Trp Thr Ser Leu 115 120 125 Lys Pro Glu Lys Ala Leu 130 INFORMATION FOR SEQ ID NO: 30. U) SEQUENCE CHARACTERISTICS. (A) LENGTH- 18 base pairs (B) TYPE:nucle c acid (D) TOPOLOGY linear Ui) MOLECULE TYPE nucleic acid (ix) FEATURE: (A) NAME/KEY: forward primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: GCTTCGGGCG CTGTAGTA 18 INFORMATION FOR SEQ ID NO: 31. U) SEQUENCE CHARACTERISTICS- (A) LENGTH: 20 base pairs (B) TYPE:nucleιc acid (D) TOPOLOGY: linear Ui) MOLECULE TYPE: nucleic acid Ux) FEATURE: (A) NAME/KEY- Reverse primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: AAAACAATCT CTTGCTGGAA 20 INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1384 base pairs (B) TYPE:nucleic acid (C) ΞTRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3 cτrrπτ__τ __-TT-T_TG A__ACA_ASXA TCTCICTCTC TGCTTEftCTT C * _Λ_3A3X_A lt.iua..3_- UL-VJGIU-CA, ; - * i-;_-_;x CΠ_-_?_23_T 'iv..-_,___.τr_ -_O__35TGA G3C?β_TS_rr ________1C1C C__-_ft_3*AΪ J_-CTCTIC__r Λ __7_ Γ_-: __ * τ -___ ι Ω(__3απ _C __O_Λ-_Λ. σ___._ -iΛ_A G__ * __-__C__Γ _i__-'iU_TG GCTCS-A GTC _-____33__y. (_-_£_f_x___aG s__rr_____A A_3ASft_3_ιc C_A-_A-_3C_G GAS__A_?I_A T_C_13___π_T C-*-_-_-*_3__fc GASRSIATTG __A__-_3XftC T_7-_T_______ AΛ3G______K_ T_ * 0_2__ * A__A__ Mtfll'JUl QΞCCIGSICλ A__AA___-C1_C __-____--___ ___-τα_a_ c C__ * Λ____?_7ΓG G__r_WAftftG _A_r_?__τ-TG CΛCATGIΛCT rø-rtrrsΛC ιv_τιua_u_ _G*T___3_T __V-._-.-W3C - -CTCCCT. _A_rι_Mβ_. GO__-_33S_T cstπαsτ-A Ac_n_rrc___3 TCT___Γ_QST c______-_τc 'i-Ti ri . TS-TD__TCC A_rcι_3_-sτ A-^'I_a_V_A GG CTTCIO. S TCCCTCA G-3ft3_GR-Cr CC_-__? 7_ C-_S_ * TC____3G TGGCΣAT T ACsW-CCTOGC ΓΓCΓTCCTC. * . c-_-_σ_x_rι_»v_: CASZAS GOC AG___TATSCT CTJAXACCCA _A_rαrι___G e_a_-___v_C-_ _cτα__sΛA_r C_-____V___r_ Ift_t_-_CGfi-3. ASIft-STSiC H-CIΛΪCIG _--V-33_-ΛΑ A__V^ΛT-__3. C__-_ * -3330C AA__AA__GA__ ICTC--G-ST _A____A_-__e ATGG * _33_rG CTCTGfiCTCC c__-t?__c_- c_7D______ * _r A__I_______& CΓG-GATE Γ AA_CI_TTCT ACTCCCCIT ___3___V_C__- C_2_ftCCITIC ___-__RT_C CITICTCP 1_C--_T_-CC T®__3_CIG_. AAJAGCCCTC T_AAA_____TT CACClATSIt. O-P-X-O-S G?__V-__A__G T_-_A_J_TT?. GA_P__A__?__Γ AI____33__3. WOTA-S-A GΓΓΪG33_UQS G__ ΓTT * _Γ_3- CTCTGOSSΓΓ _X_"ICAA_£_V_. A__ -_ATCΠ' GΠTAΛ TCTC CTΛTG? ACΓ A τ ?Λ___τ G. _-___Γ_A_X ^GJAAIAS C_CMA3__ΓT CT___3_V__3 A__-_3__T_ΛC AAW_V____G GCTg-103CC A__ATT?-.T_?»G CATC_-__C3CT ____A_r_?__3s T___A_3-_»_S_ τGr_3 * _ sxrr GSΞA___Asn TGΓΠSCCWAG ___rrcτcc_x_ T-Gi-i Ti- c-_---S3AA τGr_A3α_c CTSirrwϊπ' TA T_C_-V_rt__G AA3T INFORMATION FOR SEQ ID NO: 34: U ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1240 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34 C - T-.- 1 -'-. • i icjciv-ic I-.IUU_._LT τc__*__ft__-x A-__tΞ_cτ_τ ___ω_ * sτ_ι_c GΠA IO-S CΓSTGGRTGC ..-"i.. __- ■■■ - TI_A_»__A_- A33_AA__TG_ It33C__A_K_T ____v___3Λ__ __-H.it.Tj.tA T____M3_TG I I_____.-'(_-UB: T7G33Λ3Z TGCXXT&G a__3-_CT__-V: A3__ * __T_2__-_ ____ * _A__ * - * _TT RyJ 'AJCT α___?A____ * _3_ Λ__-33-3C-_A G_A____T- _ΞC- ___<-_V_ * __f__ C_-_3___3_CT GG?__ftC____G Aτα____-_τ_- τc?_r_ * A3?_: A__A_ΞW __ΓΓ G__αcA__α_A C_____1U_£3T G?Λ3__Λ3-X_ _.1_V______3_ _3_3_»CTC_G easa-'i - c AΛOASQCIG c_o u-v____. c∑α.ιvxcgr CCCAACSCT G3?a_---w_ A__ft_Ξ_____πττ GO«__TC--_: I_Γ_A____?A ιx -rnu3 τr___α_-_3 _3cτcr_M P-TGCl-CCC __A__T__- * 2_2- Λ_-__Gft3-G3 _-__ * I__t_GTC • V-SJI T A GCA r - j C3VS_.;V-ICA T.U»-U-__- G-_GT__T_A c-_c__τ_τ_c A?__-?___C__?- XΆGΆS-C ΓΓ C-_?___-rr_c ΓΓASΞ-S-G -___TC__ * CTA L.TI -GCTS Aλ___ * _ * _CCT_ TJ -_ * λ__AGO- TGCC-TCT-C CTGAL-Ub-A TGGCCA5__-S -____ * _3_Γ_A TCETC_?AA_3. TCC_Ϊ_3_Γ_CT crr____ * -XA_. A__CA_3_T3_; ΛW___O3_Q. GrøciAiαs. ____VA__AO: SS KrC B. TCTGΛAWAC C__ * *ΛC__M_r ___-_ * "'_&__'__ GT_CA___?___ Gr___T_TCT3 _____-V__V_f- CTGCA_Π____Ξ CACCCΓCTS- CI-U IUΠC CIXTUUUAOS A__Γ__? __A_. cri-__cτ_a_A __c_-A3_τc τιcτr_____c CCT__AΞCIA __rrc.-π-A_c .'.--TH-. . ATGCTCΓICΓ ATACTGSJT TC?D_AAAΆ_: cτs*______c CCTSTSAAG crASA c rr IIL-IUTI.-. c_33r_-__-TG3 AA__T_CTG_G T______ * _TGCA __-$J_TC__33 A3_?ιS3Λ3. TTCCTGTTCT CAG__X_____Γ SI-C-S-GCA _____7GCCTG ωv uϊ ___I_r___λ_ * A A___-It5333--. C_ * _T_-~-_--CA CAS-SATCTG C_:A;U.'- , -AA AIGM-ATXA cσ_τιv.π_G. T__V_-_MAA A?_t_____?_ T ___χτ___TC -ST-AftftftA AWiMtfAΛAA INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1146 base pairs (B) TYPE-.nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: ___T1X3____; CT1--U-AS ftG-Ciαu.,' _A___A______A τc_CA_rcα_λ τcA_π_m∑_cx GCΠ -OCTI- CΣGGGTGCCT __ TGTG33_ A_n_cr_-_G ττc__rrc?____ A_I_____A___V. C TS_0__CC ASTGAIIULTI' ICA CTIAI C * T!_--CTGT ___.1CJU.---T T?3C__CS_CT CCTGSO XG CAA 'l-ACC T__-VΞ__V_W_ _A_rr_c_-3_; A ftπ3_ccτc c.n π'_ιxτc C_-__-_ΛA__A T_ * -__B__ * _T CA__TG?_π__C _7_3-_π_TCC A3_AA__ I- g-V-TGSGIG __-3_-?_a_G ΪTOSVSWΛC IGGMTΓΠT GGICTGCTS. A__W^___CIGG C£_TΛS_T_GT __TCAJU_3_C C_3---«C_A_rG K_TW O_Ξ GAIGMTi : A__A_-?G_JV_T __V-0_ * __AA_: ___?_r_r_____: __3O___GΪGT e_acπux ci- τvm' _GCΓIA__-3_A ___Z____GCΪT C_C___C__A ACA cωcftc 'i-.-Ci.u-_- * C___A__ASCAG OCAATΪGCGG GGSCTACTGT Cl -IXftAS __G_S_CTGGA GSL- U ivJi _A_Λ_3_CΓ_A _____-___3_. G-CTCCGITC G-_ * _ " Ω" * ___ -_t * __--rr_ * τ _c___π_ι_sc TT TTTCGW- C_-__Cr__ _AC C_V__-- * I__v__ A-STCTS-AS. _CA_-CCT_RA G_- jun . c__π____r__v_: ΠΠ_A_3____Γ A-_A_∑_co-_ftC _________?_<__. L 'ΠVXTJSA _A_rτ___rc__- CGAST ACΛSC r. _ MQg GAACCTGMC TCTG-V-CCAS AAC_3y___M_ _G_____cAs: T-_-_r____AGC ATGc cTmr ___rrcs_∑_v_ C-_-_-_ * A-_V: i-CiA-V-g- A__-_-;______Γ _C_AA__CIGC IC.SS-TGCC T- CIO-TAC LTl'-O-S-O- GSSTGSTGSA -_ .G7 -__ A_ * ci--__rcc πr._rrs_ec -G-C∑AGTO- GTCTCCT-RT __-_____T_A CAGCfcA-MG __G__-_TTGA A?A3_3A33 A-U -lTJUl GTCICTOX *__T_CTG_--T _?- _r-_?_: ____AA_ΓΓAS3 crπe_-__?A KD SΣHΠG c____"j__'AA ΆΛΛTAΛUAA MΆΆAC 53 INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 316 ammo acids (B) TYPE: protein (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: i-- __-V?iv_i vnra_DSG FS_L_J-R___-> K-S-SVXAAC E-KnS-O-R NϋSDRlET I_I3VTr_XSI _^-Tζ5W__S. V_©Ξ-KG-_V NASICVF-_I ___KI__C-_2_-7. NI1-3VN_L_M ___V__-SM__? V?_OJ«___W_TN ISS_>GKV5I- ___t_G¥CXS_C- GWEAFSDSl-R ra____TCVXV AI__E?GΞ_ r _*_ (_K_SH S___K-*DC?TS SBVKEVXDKN T DSΪIKAIQ S TDTC5-T1T- _^ΛTI_X __KA _ft__H?ia3tt S?»3m?- _rϊ I_?I_S__*_r-_!-_ VI_WiΪVδSV * KKCKL INFORMATION FOR SEQ ID NO: 37: U) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 ammo acids (B) TYPE: protein (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: __-___LV__LVS IXTLISGTZ R^Λ^KIJCD YVFITGCDSG F_Tl___ft. * S0LD K^PWIAAC T__<____E__R -T___Sl___V ____VΓKT__.I VIA-ΓQWVKΞH V_Ϊ_ _-W3 _C3.SISTPSG _-__ _-3£PF ΛKVEJDWIIG KIΞΛrT SMI LVPKAK3-Λ. NVSSVMSΪVS ι_ra3Sϊcιεκ YGVEAΓ-SSL WEIB_TGVK V?_I___r-__ι TCΞVTSSASIT SNIO-W-CT SSΞIΪSI_T_E KSSAS LKSL XI-CDJSOKD LSSrøα-EH __ _3__K?RTR YSftS^ΛKLF _-_?I_S___?l_r VDAIiYWrS I£?EKP__ 54 INFORMATION FOR SEQ ID NO: 38: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 ammo acids (B) TYPE: protein (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38; W_L__*WM_-_; LR_L_RϊTF_; PCtWDHTglK YVTIT QGSG ΓSVU-ΦCC R-- K7IA_-_ W__ΞX3_____R RKTSERIEr 3Λ_H3WΛ__ tK_NR___WSLV IΦΛSISVPSG IN_3-_ KC r __3V1I3V___I__; L1IVTI_S-_P L BKftKBWV KVESΠJSCVS GGSCΪCIS K_GIΣAΓ__-S IJCCVP__Γ_V Kϋ7JIΞP-_T LTG-ftSSftFL CSNICT-VCQ TSSSΦEIΪG r<_l--S___<N l_^___DCP-i- Dl_3VV___OE I_ALTft__HPRT wsjiS∑aK-. Π-ΓPLSΪIPT Π.V__. T __L_WΓ SP_ * Π?DIKAL INFORMATION FOR SEQ ID NO:39: U ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 amino acids (B) TYPE: protein (D) TOPOLOGY: linear ( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Claims: Claims : 1. Isolated nucleic acid molecule which codes for a mammalian protein having a molecular weight of about 32 kilodaltons as determined by SDS-PAGE, wherein said protein complexes with retinol binding receptor having a molecular weight of about 63 kilodaltons as determined by SDS-PAGE, wherein the complement of said isolated nucleic acid molecule hybridizes to the nucleotide sequence of SEQ ID NO: lυ unuei. sLriiiyenL conditions. 2. The isolated nucleic acid molecule of claim 1, wherein said mammalian protein is human protein. 3. The isolated nucleic acid molecule of claim 1, wherein said mammalian protein is murine protein. 4. The isolated nucleic acid molecule of claim 1, comprising cDNA. 5. The isolated nucleic acid molecule of claim 1, comprising genomic DNA. 6. The isolated nucleic acid molecule of claim 2, consisting of SEQ ID NO: 14. 7. The isolated nucleic acid molecule of claim 2, which encodes the amino acid sequence of SEQ ID NO: 15. 8. The isolated nucleic acid molecule of claim 2, which encodes the amino acid sequence of SEQ ID NO: 15. 9. The isolated nucleic acid molecule of claim 3, which encodes the amino acid sequence of SEQ ID NO: 29. 10. Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter. 11. Expression vector comprising the isolated nucleic acid molecule of claim 2, operably linked to a promoter. 12. Cell line of bacterial cell strain, transformed or transfected with the expression vector of claim 10. 13. Cell line or bacterial cell strain, transformed or transfected with the expression vector of claim 11. 14. Isolated nucleic acid molecule which encodes a protein having retinol dehydrogenase activity, the complementary sequence of which hybridizes, under stringer conditions, to at least one nucleic acid molecule, selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23, and sequence complementary thereto. 15. The isolated nucleic acid molecule of claim 14, selected from the group consisting of SEQ ID NOS: 20, 22 and 23. 16. The isolated nucleic acid molecule of claim 14, wherein said isolated nucleic acid molecule is selected from the group consisting of SEQ ID NOS: 32, 33, 34 and 35. AMENDED CLAIMS [received by the International Bureau on 9 April 1997 (09.04.97); original claim 1 amended; remaining claims unchanged (1 page)] 1. Isolated nucleic acid molecule which codes for a human or murine protein having a molecular weight of about 32 kilodaltona as determined by SDS-PAGE, wherein said protein complexes with retinol binding receptor having a molecular weight of about 63 kilodaltons as determined by SDS-PAGE, wherein the complement of said isolated nucleic acid molecule hybridizes to the nucleotide sequence of SEQ ID NO:10 under stringent conditions. 2. The isolated nucleic acid molecule of claim l, wherein said allalian protein is human protein. 3. The isolated nucleic acid molecule of claim 1, wherein said mammalian protein is murine protein. 4. The isolated nucleic acid molecule of claim 1, comprising cDNA. 5. The isolated nucleic acid molecule of claim 1, comprising genomic DNA. 6. The isolated nucleic acid molecule of claim 2, consisting of SEO ID NO: 14. 7. The isolated nucleic acid molecule of claim 2, which encodes the amino acid sequence of SEQ ID NO: 15. 8. The isolated nucleic acid molecule of claim 2, which encodes the amino acid sequence of SEQ ID NO: 15. 9. The isolated nucleic acid molecule of claim 3, which encodes the amino acid sequence of SEQ ID NO: 29. 10. Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.

Inventors: ERICKSSON ULF, ROMERT ANNA, SIMON ANDRAS, ERICKSSON, ULF, ROMERT, ANNA, SIMON, ANDRAS
Applicants: LUDWIG INST CANCER RES, LUDWIG INSTITUTE FOR CANCER RESEARCH
Application year: 1996
Main classification: C12N1
IPC codes: C12N1, C12N5, C12N9, C12N15, C12R1